16.1.[ADDRESS_497640]-2019 
 Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 1 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 1 of 90  
CLINICAL STUDY PROTOCOL  Title: A 4 week, Phase II, multicenter, randomized, double-masked, vehicle-controlled, parallel group study with 12 weeks of follow-up to evaluate safety and efficacy of recombinant human Nerve Growth Factor (rhNGF) eye drops solution versus vehicle in patients with moderate to severe dry eye (DE).     Study Number: NGF0118   IND: [ADDRESS_497641]: rhNGF   Phase of the study:  II   Protocol Version - Date: Version No. 2.0 ‚Äì 08/AUG/2019  As per Final Amendment no. 1 ‚Äì 08/AUG/2019     STATEMENT OF CONFIDENTIALITY Information in this protocol and accompanying documents contains privileged or confidential information that is the property of Domp√© farmaceutici s.p.a. It is understood that the information will not be used, divulged, or published without prior written consent of Domp√© farmaceutici s.p.a., except to the extent such disclosure is required by [CONTACT_774].     Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 2 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 2 of 90  
DESCRIPTION OF CHANGES   Version  Modification  Date of Revision  Application  1.0 Final Version 22-JAN-2018 NA 1.1 Section [IP_ADDRESS] - line N¬∞ 5: typi[INVESTIGATOR_121868] ‚Äúmerked‚Äù modified as ‚Äúmarked‚Äù Section 5.3 ‚Äì 7th paragraph: typi[INVESTIGATOR_121868] ‚Äú‚Ä¶‚Ä¶pi[INVESTIGATOR_6343] (6 per vial) and disinfectant wipes (6 per vial)‚Äù modified as ‚Äú‚Ä¶‚Ä¶pi[INVESTIGATOR_6343] (1 per vial) and disinfectant wipes (1 per vial)‚Äù 23-JAN-2018 NA 
1.2 Section [IP_ADDRESS] ‚Äì typi[INVESTIGATOR_121868] ‚ÄúNIMP Primary Packaging, Single Pane Label For Single Vial (Blink¬Æ Tears)‚Äù has been modified as ‚ÄúNIMP Secondary Packaging, Single Pane Label For Single Vial (Blink¬Æ Tears)‚Äù Section [IP_ADDRESS] ‚Äì add the following line to the labels of NIMP: ‚ÄúFor clinical trial use only‚Äù Section [IP_ADDRESS] ‚Äì label, line 7  ‚Äì typi[INVESTIGATOR_121868] ‚ÄúBatch <vvvv>/‚Äù has been modified as ‚ÄúBatch <vvvv>‚Äù.  Section [IP_ADDRESS] ‚Äì label, line 9 (Subj. Screening # S¬Ö¬Ö¬Ö¬Ö¬Ö) and 10  (Subj. Randomization # R¬Ö¬Ö¬Ö¬Ö¬Ö) has been modified as line 9: Unique Patient N¬∞ ¬Ö¬Ö-¬Ö¬Ö¬Ö according CRO randomization procedure.  Section 5.1.1 - ‚ÄúAdministration route‚Äù typi[INVESTIGATOR_121868] ‚ÄúOphthalmic‚Äù has been modified as ‚ÄúOcular‚Äù. Section 5.1.2 ‚Äì ‚ÄúPharmaceutical form‚Äù ‚Äì ‚ÄúSterile buffered acqueous solution‚Äù has been modified as ‚ÄúEye drops Sterile buffered acqueous solution‚Äù.  Section 5.1.2  - ‚ÄúAdministration route‚Äù typi[INVESTIGATOR_121868] ‚ÄúOphthalmic‚Äù has been modified as ‚ÄúOcular‚Äù. 04-FEB-[ADDRESS_497642] been added as part of Domp√© team.   Section 4.1 ‚Äì IC N¬∞ 5 ‚ÄúBest corrected distance visual acuity (BCDVA) score of ‚â• 0.1 decimal units in both eyes at the time of study enrolment‚Äù has been modified as ‚ÄúBest corrected distance visual acuity (BCDVA) score of ‚â• 0.1 decimal units (20/200 Snellen value) in both eyes at the time of study enrolment‚Äù.  Section 7.1.3 ‚Äì typi[INVESTIGATOR_121868] ‚ÄúNumber of drop out due to worsening in symptom scores (SANDE) and/or NEI score ‚â• 50% assessed at  week 2‚Äù has been modified as ‚ÄúNumber of patients experienced a  worsening in 13-MAR-2019  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 3 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 3 of 90  
symptom scores (SANDE) and/or NEI score ‚â• 50% assessed at  week 2.   Section 6.1 and 6.2 ‚Äì information about the check and collection of patient‚Äôs diary has been added.   Section 5.1.1 and 6.2 ‚Äî the following sentence has been added ‚ÄúThe patient, only if strictly needed, can administer additional drops and must document in the patient‚Äôs diary the n¬∞ of additional drops administered for each eye‚Äù. Section 5.3 ‚Äì typi[INVESTIGATOR_121868], the following sentence has been deleted ‚Äú[‚Ä¶] in a refrigerated bag. The refrigerated bag will be used to ensure that the medications will maintain refrigeration temperatures during transport to the patient‚Äôs home.‚Äù Section 6 ‚Äì a definition of First Patient In has been added.  Section 8.2 ‚Äì typi[INVESTIGATOR_395795]. Section 2 ‚Äì ‚ÄúCheck and retrieval of patient‚Äôs diary‚Äù has been added.  Section 6.3.1 ‚Äì ‚ÄúDisease progression or worsening‚Äù has been added as primary reason of discontinuation. Section 5.4.2 ‚Äì typi[INVESTIGATOR_121868], from ‚ÄúThe exact time of study drug  administration [‚Ä¶]‚Äù has been corrected to ‚ÄúInformation about the  study drug administration [‚Ä¶]‚Äù. Section 5.2.1. ‚Äì added information about the coloured vials. 
2.[ADDRESS_497643] of abbreviations and definition of terms has been updated. Section 1 Study Centers: the sentences has been modify as follows: ‚Äú8-12 study sites in US‚Äù Section 1 Number of Patients: the section is modified as follows: ‚ÄúEligible patients will be randomized in a 1:1:1 ratio to either rhNGF eye drops solution 20 ¬µg/ml TID (‚Åì100 patients) or rhNGF eye drops solution 20 ¬µg/ml BID plus vehicle eye drop solution SID (‚Åì100 patients) or vehicle eye drop solution TID (‚Åì100 patients). Randomization will be stratified according to absence/presence of a documented diagnosis of Primary Sj√∂gren's Syndrome to ensure balanced assignment across treatment groups proportional assignment. A minimum 60 patients (20 per group) with Primary Sj√∂gren's Syndrome should be included. The enrollment of patients will be scheduled in order to assure an inclusion of approximately 240 patients without Primary Sj√∂gren's Syndrome diagnosis and at least 60 patients  with Primary Sj√∂gren's Syndrome.‚Äù Section 1.  Inclusion criteria #7: the following criteria has been modified deleting:‚ÄúIEC.‚Äù   08-AUG-[ADDRESS_497644] 2019  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 4 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 4 of 90  
Section 1. Main Inclusion criteria: the following criteria has been added as number 9: ‚ÄúPrimary Sj√∂gren's Syndrome Patients:  x Patients with a documented diagnosis of Primary Sj√∂gren's Syndrome according to the American-European Consensus Group Sj√∂gren's Syndrome Criter ia (Appendix 3; must meet either 4 out of 6 total criteria OR 3 out of 4 signs). Note: Subjects who are on systemic (oral) therapy for the treatment of Sj√∂gren's Syndrome must be on stable systemic treatment defined as the same treatment for the immediately prior 90 days‚Äù  Section 1  Exclusion criteria #4: the sentence as been modified as follows: ‚ÄúHistory of severe systemic allergy or severe ocular allergy (including seasonal conjunctivitis) or chronic conjunctivitis and/or keratitis other than dry eye‚Äù  Section 1: Main Exclusion criteria #8 ‚Äì The criteria has been modified as follows: ‚ÄúPatient had a serious adverse reaction or significant hypersensitivity to any drug or chemically related compounds or had a clinically significant allergy to drugs, foods, amide local anesthetics or other materials including commercial artificial tears, in particular commercial artificial tears containing carboxymethylcellulose (CMC) (in the opi[INVESTIGATOR_871]).‚Äù Section 1: Main Exclusion criteria #9 ‚Äì bullet point - b.has been modified as follows ‚Äúb. have a positive result at the urine pregnancy test (Screening/Baseline Day 1) or,‚Äù  Section 1:  Exclusion criteria #15: the criteria is modified as follows: ‚Äú15. Participation in a clinical trial with a new active substance during the past 6 months 60 days‚Äù Section 1: Duration of Study:  a time window is specified for the wash-out period:  ‚ÄúWash-out period (from day -8 to day-1): 7+2 days with no further treatment except commercially available preservative free artificial tears. NB: the wash-out should not be less than 7 days  Section 1  Study population: The following sentence has been added: ‚ÄúAt least 60 out of 300 patients with a documented diagnosis of Primary Sj√∂gren's Syndrome‚Äù  Section 1: Safety Endpoint: has been modifies as follows: ‚ÄúIncidence and frequency of Treatment-emergent adverse events (TEAEs), assessed throughout the study. Section: 1: Statistical Methods: The first paragraph has been modified as follows: ‚ÄúThe data collected in this study will be summarized using number of observations, mean, standard deviation (SD), median, minimum, and maximum values for quantitative variables, and frequencies for qualitative variables.‚Äù Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 5 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 5 of 90  
The second paragraph has been modified as follows:‚Äú1) Statistical Methods - Efficacy analysis  Primary endpoints will be analyzed using analysis of variance including only the treatment as main factor followed by [CONTACT_094]-planned comparisons from Vehicle and rhNGF dosages according to Williams procedure. In addition, the  primary endpoint will be summarized using descriptive statistics for continuous variables by [CONTACT_10659]. The change from baseline value will also be summarized for all post-baseline visits.  An explorative sensitivity analyses of primary endpoint will be conducted including in the analysis of variance the absence/presence of diagnosis of Primary Sj√∂gren's Syndrome and its interaction with treatments as covariates. If the interaction term is statistically significant (at the 0.10 level given its explorative nature), the treatment effects within patients with and without Primary Sj√∂gren's Syndrome will be provided.‚Äù The following paragraph has been added as third paragraph  ‚ÄúSecondary endpoints will be presented with the appropriate descriptive statistics and inferential statistics appropriate for the nature of variable analyzed will be done in order to test treatment effect.‚Äù  Section: 2. The second column title has been modified as follows:‚ÄúVisit 1 Baseline Day 1*‚Äù Section: 2. In the last line of schedule the following specification has been added:  ‚Äú*) visit window of +2 days;‚Äù Section 2.‚Äì line Ocular and Systemic Medical History: Delete ‚ÄúX‚Äù on colum Visit 1 Baseline Day 1. Section 3.1 ‚Äì  the section has been modified as follows: ‚ÄúThe study objective is to assess the efficacy and safety of rhNGF when administered as eye drops to patients with moderate to severe dry eye and to exploratively evaluate the preliminary efficacy data also in a group of dry eye patients with diagnosis of Primary Sj√∂gren's Syndrome (14)‚Äù Section 3.2 ‚Äì the first sentecce has been nodified as follows: ‚ÄúThis study will be performed at 8/12 study centers located in the [LOCATION_003]‚Äú Section 3.3 ‚Äì  the section has been modified to specify the time window for the wash-out: second sentence ‚ÄúPatients will be evaluated at screening visit (day -8), baseline (day 1+2), ‚Ä¶.‚Äù Second paragraph ‚Äú‚Ä¶free artificial tears for a period of 7 days - 9 days as maximum (day -8 to day -1+2) until the baseline visit (day 1). At the end of the wash out period (day -8 to day -1+2),‚Ä¶‚Äù Section: 3.[ADDRESS_497645]  paragraph has been modified as follows: ‚ÄúFollowing the completion of the double-blind treatment patients will Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 6 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497646] treatment and will be evaluated at the end of the safety follow-up period. During the safety follow-up period patients will not use further treatment except preservative free artificial tears provided by [CONTACT_395828] (morning, afternoon, evening ).‚Äù Section: 3.3 figure 1 has been modified to specify a time window for the wash-out period. 
 Section: 4:  The following paragraphs will be added:  ‚ÄúThe safety and efficacy of rhNGF eye drops will be investigated also in a specific subgroup of patients with hyposecretive dry eye, i.e., patients with dry eye due to primary Sj√∂gren's syndrome (2, 14). To gain information on the safety and efficacy of rhNGF in this subgroup of patients at least sixty (60) patients with a documented diagnosis of Primary Sj√∂gren's Syndrome are out of [ADDRESS_497647] already been enrolled based on the inclusion/exclusion criteria of the previous version of the study protocol. This amendment is applied only to set a minimum prespecified number of patients with Primary Sj√∂gren's Syndrome.  The nature of the resulting statistical analysis in this subgroup of patients will be explorative. Including at least y 60 subjects with documented diagnosis of Primary Sj√∂gren's Syndrome within the total sample size (20%) will have no impact on the initial assumptioms concerning sample size for the following reasons: x The previous study (NGF0216), on which sample size assumptions have been based (see section 9.1), reports a similar prevalence of patients with Primary Sj√∂gren's Syndrome in their medical history (‚Åì25% in the FAS population). x As dry eye due to Sjogren‚Äôs syndrome is a hyposecretive form of the disease, the primary endpoint is appropriate for both the whole study population and the subgroup with Sj√∂gren's syndrome‚Äù 
Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 7 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497648] already been enrolled based on the previously applied and approved inclusion/exclusion criteria Section 4.1 Inclusion criteria: the following criteria has been added as number 6: ‚ÄúSubjects with a diagnosis of Primary Sj√∂gren's Syndrome according the American-European Consensus Group Sj√∂gren's Syndrome Criter ia (Appendix 3; must meet either 4 out of 6 total criteria OR 3 out of 4 signs). Note: Subjects who are on systemic (oral) therapy for the treatment of Sj√∂gren's Syndrome must be on stable systemic treatment defined as the same treatment for the immediately prior 90 days.‚Äù Section 4.1 Inclusion criteria: general: the numbering of the inclusion criteria is revised accondingly. Section 4.2 Exclusion criteria: general: the numbering of the exclusion criteria is revised accondingly. Section 4.2 Exclusion criteria #4: to better explain the sentence has been modified as follows: ‚ÄúHistory of severe systemic allergy or severe ocular allergy (including seasonal conjunctivitis) or chronic conjunctivitis and/or keratitis other than dry eye‚Äù Section 4.2 Exclusion criteria #9 ‚Äì bullet point - b. has been modify as follows: ‚Äúb. have a positive result at the urine pregnancy test (Screening/Baseline Day 1) or,‚Äù  Section 4.2 Exclusion criteria #15:  the sentence as been modified as follows: ‚ÄúParticipation in a clinical trial with a new active substance during the past 60 days The following section has been added as section ‚Äú4.3: ELIGIBLE EYE  Process for determining the eligible eye: assuming that all the inclusion/exclusion criteria are met in both eyes, the worse eye (eligible eye) will be determined at the baseline visit using a stepladder approach, as follows: 1. Schirmer‚Äôs Test (since this is the primary endpoint)-Worse eye determined as eye with lower Schirmer I score. If Schirmer I score is the same in both eyes, worse eye will be determined by [CONTACT_317881] (cornea+conjunctival staining). 2. NEI score (cornea+conjunctival staining).  If all of the above are identical, determination of the worse eye will be based on the Investigator‚Äôs judgement, then simply use the right eye as the eligible eye.‚Äù Section 4 - general: the numbering of the section are revised Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 8 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 8 of 90  
accondingly Section 4.4 RANDOMISATION  ‚Äì [page 28] The following paragraphs have been modified as follows:   ‚ÄúEligible patients will be randomized in a 1:1:1 ratio to either rhNGF eye drops solution 20 ¬µg/ml TID (‚Åì100 patients) or rhNGF  eye drops solution 20 ¬µg/ml BID plus vehicle eye drop solution SID (‚Åì100 patients) or vehicle eye drop solution TID (‚Åì100 patients).‚Äù Randomization will be stratified according to absence/presence of a documented diagnosis of Primary Sj√∂gren's Syndrome to ensure balanced assignment across treatment groups.  Each randomized patient will be allocated with randomization number, according to the stratified randomization list. Drop outs after randomization will not be replaced.‚Äù The following paragraph have been add as last paragraph:  ‚ÄúThe enrollment of patients will be scheduled in order to assure an inclusion of approximately 240 patients wthout Primary Sj√∂gren's Syndrome diagnosis and at least 60 patients  with Primary Sj√∂gren's Syndrome. ‚Äú Section 4.[ADDRESS_497649] paragraph has been modified as follows:  ‚ÄúThe investigator will be provided with an access, password protected, to the RAVE Randomization and Trial Supply Management system (RAVE RSTM) so only in case of a medical emergency the Investigator can open the treatment allocation for a specific patient.  Besides also Domp√© Pharmacovigilance contact [CONTACT_395829], password protected, to the RAVE Randomization and Trial Supply Management system (RAVE RSTM) so if required by [CONTACT_395830] a specific Patient.‚Äù Section 6.1  Screening visits - Procedure/Assessments:  The sentence following sentence has been deleted: ‚ÄúOcular and Systemic Medical History‚Äù Screening visits - Procedure/Assessments:  The sentence‚Äù Previous ocular and systemic medication‚Äù as bben mofided as follows:   ‚Äúprevious ocular and systemic medication (prior to start the study)‚Äù  The sentence regarding the ocular surface staining has been modified to better clarify the test to be performed:  ‚ÄúOcular surface staining (NEI score - corneal and conjunctival fluorescein staining)‚Äù Visit 1 baseline - Procedure/Assessments:   Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 9 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 9 of 90  
The sentence‚Äù Ocular and systemic medication‚Äù as bben mofided as follows:   ‚ÄúPrevious ocular and systemic medication (prior to start the study‚Äù  The sentence regarding the ocular surface staining has been modified to better clarify the test to be performed:  ‚ÄúOcular surface staining (NEI score - corneal and conjunctival fluorescein staining)‚Äù  The order of the procedure has been revised to clarify that the patient elegiliby [CONTACT_395831]:  The following procedures will be performed (order below is mandatory): ¬æ Pregnancy test for female patients of childbirth potential ¬æ Ocular and systemic medical history ¬æ Previous ocular and systemic medications (prior to the treatment) ¬æ Ocular examination of both eyes: x Assessment by [CONTACT_58212] x Assessment by [CONTACT_317891] x Assessment by [CONTACT_28973]-5D-3L questionnaire x Assessment of best corrected distance visual acuity (BCDVA) x External Ocular Examination x Schirmer test  I (without anesthesia)  x Slit-lamp examination (SLE) to assess the eyelid (Meibomian glands), eyelid (erythema), eyelid (edema), lashes, conjunctiva erythema, lens, iris, anterior chamber, corneal horizontal diameter x TFBUT x Ocular surface staining (NEI score ‚Äì corneal and conjunctival fluorescein staining) x Schirmer test II (with anesthesia) x Laser scanning confocal microscopy to assess goblet cells density (only selected sites)  x Corneal endothelium and stroma evaluation (only the sites having a confocal microscope will do this type of evaluation)  ¬æ Patient eligibility: Inclusion/exclusion criteria evaluation ¬æ Randomization ¬æ Study drug dispensation ¬æ Preservative free artificial tears dispensation  ¬æ AE collection Visit 2 Week 2 - Procedure/Assessments    The sentence regarding the slit-lamp examination as been modified as follows: Slit-lamp examination (SLE) to assess the eyelid (Meibomian glands), eyelid (erythema), eyelid (edema), lashes, conjunctiva erythema, lens, iris, anterior chamber, corneal horizontal diameter. The sentence regarding the ocular surface staining has been modified to better clarify the test to be performed:  ‚ÄúOcular surface staining (NEI score - corneal and conjunctival fluorescein staining)‚Äù  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 10 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 10 of 90  
Visit 3 Week 4 - Procedure/Assessments The sentence regarding the slit-lamp examination as been modified as follows:Slit-lamp examination (SLE) to assess the eyelid (Meibomian glands), eyelid (erythema), eyelid (edema), lashes, conjunctiva erythema, lens, iris, anterior chamber, corneal horizontal diameter. The sentence regarding the ocular surface staining has been modified to better clarify the test to be performed:  ‚ÄúOcular surface staining (NEI score - corneal and conjunctival fluorescein staining)‚Äù  Section 6.2: Visit 4 Follow up Week 8 - Procedure/Assessments Visit 5 Follow up Week 12 - Procedure/Assessments Visit 6 Follow up Week 16 - Procedure/Assessments The following sentences has been modified as follows: ‚ÄúSlit-lamp examination (SLE) to assess the eyelid (Meibomian glands), eyelid (erythema), eyelid (edema), lashes, conjunctiva erythema, lens, iris, anterior chamber, corneal horizontal diameter. The following sentences has been modified as follows: ‚ÄúOcular surface staining (NEI score - corneal and conjunctival fluorescein staining)‚Äù  Section 6.3.2.       Discontinuation procedures  [page 49] The last bullet point has been modified as follows:   ‚Äúrecord in the eCRF any follow-up if the patient is withdrawn for an AE. AE‚Äôs should be followed until resolution.‚Äù Section 7.1.3.: The last bullet point has been modified as follows:   ‚ÄúChange from baseline in goblet cells density Vs week 4.‚Äù The following section has been added as section 7.1.5 ‚Äú7.1.5. Stratification according to absence /presence of Primary Sj√∂gren's Syndrome x The primary, secondary, explorative and safety endpoints (see 7.1.1, .7.1.2 7.13 & 7.1.4) will be also evaluated within each stratification subgroup (absence/presence of Primary Sj√∂gren's Syndrome). Section 9: The first paragraph has been modified has follows: ‚ÄúThe data collected in this study will be summarized using number of observations, mean, standard deviation (SD), median, minimum, and maximum values for quantitative variables, and frequencies for qualitative variables.‚Äù Section 9.1.:  The second paragraph, first bullet point has been modified as follows:‚ÄúThe probability level (Œ±) for one-sided test is set at 0.025 (see table 12.1.2 at page 298 in Chow et al., 2008) and the power level at approximately 90%.‚Äù The following paragraph has been added as last paragraph: Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 11 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 11 of 90  
‚ÄúThe inclusion of approximately 60 subjects with documented diagnosis of Primary Sj√∂gren's Syndrome within the planned [ADDRESS_497650] on the initial study assumptions (Standard Deviation of 10.78 and DELTA of 5.3 mm) because the patients could have been enrolled based on the previous criteria on which sample size was based. Moreover, a similar prevalence of patients with Primary Sj√∂gren's Syndrome has already been reported in the NGF0216 medical history (‚Åì25% of patient the FAS population).‚Äù Section 9.2. The first paragraph has been modified as follows:  ‚ÄúThe Screened Population will consist of all patients with the signature [CONTACT_28513], the assignment of a PID number and regardless the completion of all the screening procedures.‚Äù  The second  paragraph has been modified as follows: ‚ÄúThe Eligible Population will consist of all patients with all inclusion/exclusion criteria met. Otherwise the patientspatient will be defined as screening failure.‚Äù  Section 9.3. The  formula has been implemented has follows: ùêéùêØùêûùê´ùêöùê•ùê• ùêúùê®ùê¶ùê©ùê•ùê¢ùêöùêßùêúùêû =ùüèùüéùüé‚àó(ùêçùêÆùê¶ùêõùêûùê´ ùê®ùêü ùêØùê¢ùêöùê•ùê¨ ùêùùê¢ùê¨ùê©ùêûùêßùê¨ùêûùêù ‚Äì ùêçùêÆùê¶ùêõùêûùê´ ùê®ùêü ùêÆùêßùêÆùê¨ùêûùêù ùêØùê¢ùêöùê•ùê¨ ùê´ùêûùê≠ùêÆùê´ùêßùêûùêù)ùüë‚àó(ùëµùíñùíéùíÉùíÜùíìùíî ùíêùíá ùíÖùíÇùíöùíî ùíêùíè ùíïùíìùíÜùíÇùíïùíéùíÜùíèùíï)  ùêÇùê®ùê¶ùê©ùê•ùê¢ùêöùêßùêúùêû ùêüùê®ùê´ ùê≠ùê°ùêû ùêûùê•ùê¢ùê†ùê¢ùêõùê•ùêû ùêûùê≤ùêû =ùüèùüéùüé‚àó(ùêçùêÆùê¶ùêõùêûùê´ ùê®ùêü  ùêùùê´ùê®ùê©ùê¨ ùêöùêùùê¶ùê¢ùêßùê¢ùê¨ùê≠ùêûùê´ùêûùêù ùê≠ùê® ùê≠ùê°ùêû ùêûùê•ùê¢ùê†ùê¢ùêõùê•ùêû ùêûùê≤ùêû)ùüë‚àó(ùëµùíñùíéùíÉùíÜùíìùíî ùíêùíá ùíÖùíÇùíöùíî ùíêùíè ùíïùíìùíÜùíÇùíïùíéùíÜùíèùíï)‚Äù  Section 9.4.1.: The first paragraph has been modified has follows: ‚ÄúThe Enrolled Set will consist of all patients who signed the ICF. This analysis set will be used for demographic, baseline and background characteristics.‚Äù The second paragraph has been modified as follows:Safety Population -The Safety Population (SAF) will consist of all randomized patients who took at least one dose of IP. This analysis set will be used for the safety analysis. Patients will be analyzed according to the treatment received.‚Äù The third paragraphhas been modified has follows:  ‚ÄúFull Analysis Set - Full Analysis Set (FAS) will consist of all randomized patients who took at least one dose of IP and who have at least one post-baseline efficacy measurement for the primary endpoint. This analysis set will be used for the primary efficacy analysis. Patients will be analyzed according to the randomized treatment.‚Äù The fourth  paragraph has been modified as follows:  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 12 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 12 of 90  
‚ÄúPer Protocol Set - ‚ÄúPer Protocol Set (PP) will consist of all patients in the FAS who fulfil the study protocol requirements in terms of investigational medicinal product intake and collection of primary efficacy data and with no major deviations that may affect study results. This analysis set will be used for supportive efficacy analysis. Patients will be analyzed according to the treatment received. Each patient will be coded by [CONTACT_395832], SAF, FAS and PP.‚Äù Section 9.4.3.:The third bullet point has been modified as follows: ‚Äúmajor deviation from inclusion/exclusion criteria (eligibility violations).‚Äù Section 9.4.4.: The paragraph has been modified as follows:   ‚ÄúDemographic and baseline characteristics will be descriptively summarized per treatment group according to their nature.‚Äù  Section 9.5.: The  paragraph has been modified as follows::  ‚ÄúPrimary endpoint will be analyzed using analysis of variance including only the treatment as main factor followed by [CONTACT_094]-planned comparisons from Vehicle and rhNGF dosages according to Williams procedure.In addition, primary endpoint will be summarized using descriptive statistics for continuous variables by [CONTACT_10659]. The change from baseline value will also be summarized for all post-baseline visits. An explorative sensitivity analysis of primary endpoint will be conducted including in the analysis of variance the absence/presence of diagnosis of Primary Sj√∂gren's Syndrome and its interaction with treatments as covariates. If the interaction term is statistically significant (at the 0.10 level given its explorative nature), the treatment effects within patients with and without Primary Sj√∂gren's Syndrome will be provided. Secondary endpoints will be presented by [CONTACT_395833].  Changes from baseline in global SANDE score, Schirmer test II, NEI scales, TFBUT,  IDEEL, PGIC and EQ-5D-3L scores [ADDRESS_497651] I (primary endpoint) in order to test treatment effect. Difference between treatment groupsgroup (Each active dose vs Placebo), in the percentage of patients who experienced a worsening in SANDE scores and/or NEI score will be tested using a chi-square test.  Explorative endpoints will be summarized by [CONTACT_395833]. Any statistical testing will be descriptive in nature. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 13 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 13 of 90  
Additional details on the analyses will be provided in the statistical analysis plan.‚Äù Section 9.5.1: The send and third paragraphs have been modified from: ‚ÄúTreatment-emergent AEs are all events occurring or worsening after the first dose of the IMP. Treatment-emergent AEs will be summarized by [CONTACT_1570]. The number and percentage of patients with any AE and the number of TEAEs will be tabulated by [CONTACT_3592], seriousness, relationship to treatment and severity. Individual AEs will be listed in patient data listings.‚Äù A new section has been added:  ‚ÄúSection 9.5.3     Subgroup analysis  Sub-group analyses of primary, secondary and explorative endpoints will be performed on patients with the Sj√∂gren's syndrome for explorative purpose. Statistical details will be reported in the SAP‚Äù Section 13:Reference 2: The reference has been updated as follows TFOS DEWS II REPORT. Ocul Surf 2017; 15(3):269-283 Section 13: the following reference has been added:‚Äù14. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sj√∂gren‚Äôs syndrome: a revised version of the European criteria proposed by [CONTACT_317921]-European Consensus Group. Ann Rheum Dis 2002; 61:554‚Äì558.  Section 14.1: the following sentence hasebeen modify as follows: ‚ÄúElisa Greco, Clinical Research Specialist‚Äù The following section 14.3 has been added: ‚ÄúAppendix 3 American-European Consensus Criteria for Sj√∂gren‚Äôs Syndrome‚Äù Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 14 of 91
Study Protocol: NGF0118 
Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497652] INFORMATION SPONSOR Medical Expert 
[INVESTIGATOR_395858] √© farmaceutici S.p.A., V ia S. Martino 12, [ZIP_CODE] Milan, Italy 
Phon e: [PHONE_1046] 
Fax: [PHONE_1047]  
Flavio Mantelli ‚Äì Chief Medical Officer 
Email to: [EMAIL_1086]  
or Fax: [PHONE_1047] 
Pi[INVESTIGATOR_395796] ‚Äì Global Head Clinical Development 
Email to:  [EMAIL_7577]  
or Fax: [PHONE_1047]  
Mauro P Ferrari ‚Äì Clinical Senior Development Manager 
Email to: [EMAIL_7578]  
or Fax: [PHONE_1047] 
Elisa Greco- Clinical Research Officer 
Email to:  [EMAIL_7579]  
or Fax: [PHONE_1047]  
Beth Butler ‚Äì Clinical Development Manager 
Email to: [EMAIL_7580]  
Laura Boga, Senior Safety Manager  
Email to: [EMAIL_1085]  
or Fax: [PHONE_1048] CLINICAL RESEARCH ORGANIZATION Syneos Health,  Corporate Headquarters [ADDRESS_497653] Morrisville, NC [ZIP_CODE]      Phone: +[PHONE_4340]  Fax: +[PHONE_8233] Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 15 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497654] of Abbreviations and Definitions of Terms   .............................................................................. 19 1. STUDY SYNOPSIS ......................................................................................................... 21 2. SCHEDULE OF EVALUATIONS ................................................................................. 28 2.1. BACKGROUND INFORMATION .................................................................................. 29 2.1.1. Nerve Growth Factor - Overview ...................................................................................... 29 2.1.2. Chemical And Formulation Data ....................................................................................... 29 2.1.3. Rationale for rhNGF therapy in patients with dry eye ....................................................... 30 2.2. A SUMMARY OF CLINICAL DATA ............................................................................. 31 2.3. STUDY RATIONALE ...................................................................................................... 32 2.3.1. Risk assessment/benefit evaluation.................................................................................... [ADDRESS_497655] (NIMP) ....................................... 42 Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 16 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497656] ............................................................ 42 5.2. FORMULATION AND PACKAGING ............................................................................ 44 5.2.1. Labeling ............................................................................................................................. 44 5.3. STORAGE AND HANDLING OF IMP ........................................................................... 48 5.4. DOSE, ROUTE AND SCHEDULE OF IMP ADMINISTRATION ................................ 50 5.4.1. Administration route .......................................................................................................... 50 5.4.2. Dose regimen ..................................................................................................................... 50 5.5. ACCOUNTABILITY OF THE IMP ................................................................................. 50 5.6. CONCOMITANT MEDICATION .................................................................................... 51 6. STUDY PROCEDURE AND ASSESSMENTS ............................................................ 52 6.1. SCREENING AND RANDOMIZATION VISITS ........................................................... 53 6.2. STUDY VISITS AND FOLLOW-UP ASSESSMENTS .................................................. 55 6.3. EARLY WITHDRAWAL FROM THERAPY OR ASSESSMENT ................................ 60 6.3.1. Primary Reason For Discontinuation From The Study ...................................................... 60 6.3.2. Discontinuation procedures ............................................................................................... 61 6.3.3. Replacement procedure ...................................................................................................... 61 6.4. END OF STUDY ............................................................................................................... 61 7. ENDPOINTS .................................................................................................................... 62 7.1. STUDY ENDPOINTS ....................................................................................................... 62 7.1.1. Primary endpoint................................................................................................................ 62 7.1.2. Secondary endpoints .......................................................................................................... 62 7.1.3. Exploratory endpoint ......................................................................................................... 62 7.1.4. Safety endpoint .................................................................................................................. 63 7.1.5. Stratification according to absence /presence of Primary Sj√∂gren's Syndrome ................. 63 8. EVALUATION OF ADVERSE EVENTS AND SAFETY INFORMATION ............ 64 8.1. DEFINITIONS................................................................................................................... 64 8.2. ADVERSE EVENT (AE) MONITORING ....................................................................... [ADDRESS_497657] ........................................................... 68 8.3.2. Severity of AEs .................................................................................................................. 68 8.4. SERIOUS ADVERSE EVENT REPORTING .................................................................. 69 8.4.1. Reporting Procedure for Investigators to Domp√© and CRO .............................................. 69 8.4.2. Conditions that should not be reported as serious adverse events ..................................... 70 8.4.3. Reporting Procedure to IRB and to Regulatory Authorities .............................................. 71 8.4.4. Periodical Reporting to Regulatory Authorities ................................................................ 72 8.5. UNMASKING OF THE STUDY TREATMENT ............................................................. 72 Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 17 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 17 of 90  
8.6. FOLLOW-UP OF PATIENTS WITH ADVERSE EVENTS (AES) ................................ [ADDRESS_497658] KEEPI[INVESTIGATOR_1645] .......................................................... 82 11.1. CASE REPORT FORMS .................................................................................................. 82 11.2. DATA MANAGEMENT .................................................................................................. 82 11.3. DOCUMENTATION REQUIRED PRIOR TO INITIATION OF AND DURING THE STUDY .............................................................................................................................. 82 11.4. ESSENTIAL DOCUMENT RETENTION ....................................................................... 83 12. STUDY MANAGEMENT ............................................................................................... 84 12.1. MONITORING .................................................................................................................. 84 Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 18 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 18 of 90  
12.2. ACCESS TO RECORDS ................................................................................................... 84 12.3. AUDIT AND INSPECTION ............................................................................................. 84 12.4. PROTOCOL AMENDMENTS ......................................................................................... 84 12.5. DISCONTINUATION OF THE STUDY ......................................................................... 85 12.6. PUBLICATIONS............................................................................................................... 85 13. REFERENCES................................................................................................................. 86 14 APPENDICES .................................................................................................................. 87 14.1 APPENDIX 1-SPONSOR APPROVAL PAGE ............................................................................ 87 14.2 APPENDIX 2-INVESTIGATOR‚ÄôS SIGNATURE [CONTACT_1783] ............................................................ 88 14.3 APPENDIX 3AMERICAN-EUROPEAN CONSENSUS CRITERIA FOR SJ√ñGREN‚ÄôS SYNDROME ..................................................................................................................... 89   Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 19 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497659] Research Organization DE Dry Eye DHHS Department of Health and Human Services DNA Deoxyribonucleic  DSUR  Development Safety Update Report e-CRF/CRF Electronic/Case Report Form EDC Electronic Data Capture EMA European Medicine Agency EQ-5D-3L EuroQol group [ADDRESS_497660] IUD Intra Uterine Device LNGFR Low-affinity NGF receptor Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 20 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497661] Deviation SID Semel in die SLE Slit-lamp examination SOC System Organ Class S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction TEAE Treatment Emergent Advers Event TFBUT Tear Film Break-Up Time  TID Tris in die  TrkA Tropomyosin receptor kinase A Vs Versus ¬ß Section Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 21 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 21 of 90  
1. STUDY SYNOPSIS   CLINICAL STUDY SYNOPSIS:  Study Number  NGF0118 Title of Study  A 4 weeks, Phase II, multicenter, randomized, double-masked, vehicle-controlled, parallel group study with 12 weeks of follow-up to evaluate safety and efficacy of recombinant human Nerve Growth Factor (rhNGF) eye drops solution versus vehicle, in patients with moderate to severe dry eye (DE). IND N¬∞ 115892 Study Centers (Country)  8-12 study sites in US Development Phase  Phase II Objective  The primary objective of this study is to assess the efficacy and safety of rhNGF eye drops at 20 ¬µg/ml concentration administered two or three times daily for 4 weeks in patients with moderate to severe dry eye. The trial is designed to perform dose ranging. Study Design and Methodology  This is a phase II,  multicenter, randomized, double masked, parallel arm, vehicle-controlled trial. 
Number of Patients  Eligible patients will be randomized in a 1:1:1 ratio to either rhNGF eye drops solution 20 ¬µg/ml TID (‚Åì100 patients) or rhNGF  eye drops solution 20 ¬µg/ml BID plus vehicle eye drop solution SID (‚Åì100 patients) or vehicle eye drop solution TID (‚Åì100 patients). Randomization will be stratified according to absence/presence of a documented diagnosis of Primary Sj√∂gren's Syndrome to ensure balanced assignment across treatment groups. A minimum of 60 patients (20 per group) with Primary Sj√∂gren's Syndrome should be included. The enrollment of patients will be scheduled in order to assure an inclusion of approximately 240 patients without Primary Sj√∂gren's Syndrome diagnosis and at least 60 patients  with Primary Sj√∂gren's Syndrome. Main Inclusion criteria  1. Male or female aged ‚â• 18 years 2. Patients with moderate to severe dry eye characterized by [CONTACT_58187]: a. Corneal and/or conjunctival staining with fluorescein using National Eye Institute (NEI) grading system > 3 Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 22 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 22 of 90  
b. SANDE questionnaire >[ADDRESS_497662] I (without anaesthesia) >2mm <10 mm/5 minutes d. Tear film break-up time (TFBUT) < 10 seconds in the worse eye 3. The same eye (eligible eye) must fulfill all the above criteria  4. Patients diagnosed with dry eye at least 6 months before enrolment (current use or recommended use of artificial tears for the treatment of Dry Eye) 5. Best corrected distance visual acuity (BCDVA) score of ‚â• 0.1 decimal units (20/200 Snellen value) in both eyes at the time of study enrolment 6. If a female of childbearing potential, have a negative pregnancy test  7. Only patients who satisfy all Informed Consent requirements may be included in the study. The patient and/or his/her legal representative must read, sign and date the Informed Consent document before any study-related procedures are performed. The Informed Consent form signed by [CONTACT_8097]/or legal representative must have been approved by [CONTACT_395834] 8. Patients must have the ability and willingness to comply with study procedures. 9. Primary Sj√∂gren's Syndrome Patients:   x Patients with a documented diagnosis of Primary Sj√∂gren's Syndrome according the American-European Consensus Group Sj√∂gren's Syndrome Criteria (Appendix 3; must meet either 4 out of 6 total criteria OR 3 out of 4 signs). Note: Subjects who are on systemic (oral) therapy for the treatment of Sj√∂gren's Syndrome must be on stable systemic treatment defined as the same treatment for the immediately prior 90 days.  Main exclusion criteria 1. Inability to speak and understand the local language sufficiently to understand the nature of the study, to provide written informed consent, and to allow the completion of all study assessments;  2. Evidence of an active ocular infection, in either eye  3. Presence of any other ocular disorder or condition requiring topi[INVESTIGATOR_395797] 4. History of severe systemic allergy or severe ocular allergy (including seasonal conjunctivitis) or chronic conjunctivitis and/or keratitis other than dry eye 5. Intraocular inflammation defined as Tyndall score >[ADDRESS_497663] 5 years 7. Systemic disease not stabilized within 1 month before Screening Visit (e.g. diabetes with glycemia out of range, thyroid malfunction..) or judged by [CONTACT_317880] (e.g. current systemic infections) or with a condition incompatible with the frequent assessment required by [CONTACT_1758] 8. Patient had a serious adverse reaction or significant hypersensitivity to any drug or chemically related compounds or had a clinically significant allergy to drugs, foods, Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 23 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 23 of 90  
amide local anesthetics or other materials including commercial artificial tears, in particular commercial artificial tears containing carboxymethylcellulose (CMC) (in the opi[INVESTIGATOR_871]) 9. Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:  a. are currently pregnant or,  have a positive result at the urine pregnancy test (Screening/Baseline Day 1) or,  intend to become pregnant during the study treatment period or,  are breast-feeding or, are not willing to use highly effective birth control measures, such as: hormonal contraceptives - oral, implanted, transdermal, or injected - and/or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or IUD - during the entire course of and [ADDRESS_497664] of the study, confound the interpretation of the study results, or endanger the patient‚Äôs well-being  11. Use of topi[INVESTIGATOR_8579], topi[INVESTIGATOR_395798] [ADDRESS_497665] lenses or punctum plug use during the study (previous use not an exclusion criteria but must be discontinued at the screening visit) 13. History of drug addiction or alcohol abuse 14. Any prior ocular surgery (including refractive palpebral and cataract surgery) if within [ADDRESS_497666]/Reference Product, Dosage and Mode of Administration  Test product is rhNGF 20 ¬µg/ml; reference product is vehicle. Test and reference will be instilled in both eyes according to the following scheme:  Group 1:  one drop of rhNGF 20 ¬µg/ml will be instilled in both eyes three times daily (every 6-8 hours, e.g. 7:00 am, 02:00 pm; 09:00 pm).  Group 2:  one drop of rhNGF 20 ¬µg/ml will be instilled in both eyes two times daily plus one drop (40 ¬µL) of vehicle will be instilled in both eyes once daily (every 6-8 hours, e.g. 7:00 am, 02:00 pm; 09:00 pm). NB: rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon.  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 24 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 24 of 90  
Group 3: vehicle eye one drop will be instilled in both eyes      three times daily (every 6-8 hours, e.g. 7:00 am, 02:00 pm; 09:00 pm). The IMP will be provided in a monthly box containing 28 daily boxes. Each daily box contains three marked vials one for each administration (e.g. 1- Morning, 2- Afternoon and 3- Evening). Together with the IMP monthly box, the patients will be provided with a sufficient number of pi[INVESTIGATOR_395799].  
Duration of Study Patients will be evaluated at screening visit (day -8), baseline (day 1+2), week 2 (day 14r2), week 4 (day 28r2) or early exit and week 8 (day 56¬±2), 12 (day 84r4) and 16 (day 112r7) weeks of follow-up. Screning Visit (day -8): all procedure for inclusion will be performed.  Wash-out period (from day -8 to day-1): 7 +2 days with no further treatment except commercially available preservative free artificial tears. NB: the wash-out should not be less than 7 days Treatment: eligible patients will be randomized 1:1:1 and treated for 4 weeks with either rhNGF eye drops 20 ¬µg/ml TID, rhNGF eye drops 20 ¬µg/ml BID and vehicle SID  or vehicle TID.  During the treatment period only the experimental IMP is allowed. But, if strictly needed, the patient can use commercially available preservative free artificial tears, provided by [CONTACT_2728].  Follow up: [ADDRESS_497667] document in the patient‚Äôs diary the n¬∞ of additional drops administered for each eye.Maximum total study duration: [ADDRESS_497668] 60 out of 300 patients with a documented of Primary Sj√∂gren's Syndrome should be included .    Primary Efficacy Endpoint  Primary end-point: 1.  Change from baseline in Schirmer I test (without Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 25 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 25 of 90  
anesthesia) Vs week 4.  
Secondary Efficacy Endpoints  Secondary end-points: 1. Change from baseline in Symptoms questionnaire (SANDE) scores for severity and frequency Vs week 4;  2. Change from baseline in Schirmer II test (with anesthesia) Vs week 4; 3.  Change from baseline in Cornea and conjunctiva vital staining with fluorescein (National Eye Institute [NEI] scales) Vs week 4; 4.  Change from baseline in Tear Film Break-Up Time (TFBUT) Vs week 4  5. Number of patients who experienced  a worsening in symptom scores (SANDE) and/or NEI score ‚â• 50% assessed at  week 4; 6. Quality of life (Impact of Dry Eye on Everyday Life (IDEEL) questionnaire;  7. Patient global Impression of change (PGIC);  8. EQ-5D-3L. 
Exploratory Endpoints 1. Correlation between sign and symptom scores; 2. Proportion and frequency of preservative free artificial tears use (n¬∞ drops/day) during the treatment period; 3. Frequency of preservative free artificial tears use (n¬∞ drops/day) during the follow up period. 4. Change from baseline in Schirmer I test (without anesthesia) Vs week 2;  5. Change from baseline in Symptoms questionnaire (SANDE) scores for severity and frequency Vs week 2;  6. Change from baseline in Cornea and conjunctiva vital staining with fluorescein (National Eye Institute [NEI] scales) Vs week 2; 7. Change from baseline in Tear Film Break-Up Time (TFBUT) Vs week 2; 8. Number of patients who experienced a  worsening in symptom scores (SANDE) and/or NEI score ‚â• 50% assessed at  week 2; 9. Change from baseline in goblet cells density Vs week Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 26 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 26 of 90  
4.  Safety Endpoint 1. Incidence and frequency of Treatment-emergent adverse events (TEAEs), assessed throughout the study. 
Statistical Methods The data collected in this study will be summarized using number of observations, mean, standard deviation (SD), median, minimum, and maximum values for quantitative variables, and frequencies for qualitative variables.  1) Efficacy analysis Primary endpoints will be analyzed using analysis of variance including only the treatment as main factor followed by [CONTACT_094]-planned comparisons from Vehicle and rhNGF dosages according to Williams procedure. In addition, primary endpoint will be summarized using descriptive statistics for continuous variables by [CONTACT_10659]. The change from baseline value will also be summarized for all post-baseline visits. An explorative sensitivity analysis of primary endpoint will be conducted including in the analysis of variance the absence/presence of diagnosis of Primary Sj√∂gren's Syndrome and its interaction with treatments as covariates. If the interaction term is statistically significant (at the 0.10 level given its explorative nature), the treatment effects within patients with and without Primary Sj√∂gren's Syndrome will be provided. It will be summarized using descriptive statistics for continuous variables by [CONTACT_10659]. The change from baseline value will also be summarized for all post-baseline visits. Secondary endpoints will be presented with the appropriate descriptive statistics and inferential statistics appropriate for the nature of variable analyzed will be done in order to test treatment effect.    Explorative endpoints will be summarized by [CONTACT_395833]. Any statistical testing will be descriptive in nature.  2) Safety analysis AEs Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 27 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 27 of 90  
Adverse events (AEs) will be coded by [CONTACT_1196] (SOC) and Preferred Term (PT), using the Medical Dictionary for Regulatory Activities (MedDRA). Individual AEs will be listed in patient data listings.  AEs will be summarized by [CONTACT_1570]. The number and percentage of patients with any AE and the number of TEAEs will be tabulated by [CONTACT_3592], seriousness, relationship to treatment and severity.   3) Quality of life analysis  Data recorded in the questionnaires of quality of life will be presented with appropriate descriptive statistics and processed with appropriate inferential test.    Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 28 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 28 of 90  
2. SCHEDULE OF EVALUATIONS  Study procedures Screening (Day-8) Visit 1 Baseline Day 1* Visit 2 Week 2 Visit 3 End of treatment Week 4a Visit 4 follow-up Week 8a Visit 5 follow-up Week 12b  Visit 6 follow-up Week 16c  Informed Consent X       Inclusion/Exclusion Criteria X X      Pregnancy Test X X     X Randomization  X      Demographics X       Ocular and Systemic Medical History X       Previous Ocular And Systemic Medications X X      SANDE X X X X X X X IDEEL X X  X X X X EQ-5D-3L X X  X X X X PGIC    X X X X BCDVA X X X X X X X External Ocular Examination X X X X X X X Schirmer test I X X X X X X X Slit Lamp Examination X X X X X X X TFBUT X X X X X X X Fluorescein staining (NEI scale) X X X X X X X Schirmer test II  X  X   X Confocal microscopy to assess goblet cells density d  X  X   X Corneal endothelium and stroma evaluation as per confocal microscopy e  X  X   X Study drug dispensation  Xf      Verify patient study medication dosing compliance    X    Concomitant Ocular And Systemic Medications   X X X X X Frequency of preservative free artificial tears use (n¬∞ drops/day)   Xg Xg Xh Xh Xh Check and retrieval of patient‚Äôs diary   Xi X X X X Record AEs X X X X X X X Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 29 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 29 of 90  
Study procedures Screening (Day-8) Visit 1 Baseline Day 1* Visit 2 Week 2 Visit 3 End of treatment Week 4a Visit 4 follow-up Week 8a Visit 5 follow-up Week 12b  Visit 6 follow-up Week 16c  *) visit window of +2 days;  a) Visit window of ¬± 2 days; b) Visit window of ¬± 4 days; c) Visit window of  ¬± 7 days; d) only selected sites; e) Only the sites having a confocal microscope will do this type of evaluation; f) a monthly box will be given to the patients;       g) During the treatment period patients can use, if strictly needed, the preservative free artificial tears; h) During the follow up period it is allowed to use the preservative free artificial tears; i) During the visit 2, week 2, the PI [INVESTIGATOR_1660] a delegate must only check if the patient has correctly completed the diary.   2.1. BACKGROUND INFORMATION 2.1.1. Nerve Growth Factor - Overview   Nerve growth factor (NGF) is a polypeptide essential for the survival and growth of sympathetic and sensory neurons, and for differentiation of neurons in the central nervous system. It binds with at least two classes of receptors: high-affinity tropomyosin receptor kinase A (TrkA), a transmembrane tyrosine kinase, and low-affinity NGF receptor (LNGFR), also known as p75 neurotrophin receptor (p75NTR).  NGF and TrkA are expressed in the anterior segment of the eye (iris, ciliary body, lens, cornea and conjunctiva), and NGF is released in the aqueous humor. Several pi[INVESTIGATOR_395800], playing a crucial role in the physiopathology of several anterior ocular segment diseases.   2.1.2. Chemical And Formulation Data   As recombinant human NGF (rhNGF) production in mammalian cells does not achieve adequate yields, a manufacturing process based on the use of recombinant Escherichia coli (E. coli) has been developed. However, because the biological activity of NGF relies on the formation of three disulfide bonds, and because disulfide bonds cannot occur in the reducing cytosol, the purification and renaturation of NGF produced in E. coli is problematic. Based on the knowledge that the prosequence increases the yield and rate of refolding of NGF, we have developed a manufacturing process starting from proNGF. After expression of proNGF in E. coli, the insoluble protein is isolated in the form of insoluble inactive aggregates (inclusion bodies), solubilized in a strong denaturing agent and subsequently converted into the natural conformation, which is determined by [CONTACT_317863]. Biologically active rhNGF is finally obtained by [CONTACT_317864]. The deoxyribonucleic acid (DNA) sequence of human proNGF has been optimized for E coli expression (codon adjustment) and two changes in the furin cleavage site, R101V and K103A, have been introduced. These two changes are important Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 30 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 30 of 90  
to ensure a homogeneous rhNGF preparation during the process with the mature protein starting with serine 105.  2.1.3. Rationale for rhNGF therapy in patients with dry eye  Dry eye is a chronic inflammatory condition of the ocular surface with severe symptoms and visual impairment, leading to worse efficiency to perform duties for an average of 184 work days and resulting in an average loss of productivity estimated in 5,000USD per year per patient (1).  Dry eye results from systemic diseases (Sj√∂gren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, Stevens-Johnson syndrome, thyroid disease, Bell's palsy), ocular conditions (Meibomian gland dysfunction, blepharitis, ocular rosacea, corneal dystrophies), elective surgeries (refractive surgery, blepharoplasty), eyelid conditions (lagophthalmos, entropi[INVESTIGATOR_2394]/ectropi[INVESTIGATOR_2394]), cranial surgeries, side effects of drugs (antihistamines, diuretics, beta-blockers), ocular injuries and burns, chemotherapy and radiation, aging, menopause, etc. (2).  Dry eye pathogenesis is multifactorial; however, a number of common mechanisms can be identified: (i) chronic inflammation of the conjunctiva; (ii) decrease of ocular surface sensitivity; (iii) impairment of quantity of tears and/or quality of the tear film, including tear film hyperosmolarity; (iv) changes of conjunctival epi[INVESTIGATOR_395801]; (v) corneal epi[INVESTIGATOR_58158].  Until now, treatment has been limited to the use of artificial tears to temporarily improve lubrication of the ocular surface, or the use of steroids to decrease the inflammatory reaction. However, chronic use of steroids is associated with severe complications such as cataract and glaucoma (2). Cyclosporine eye drop therapy for dry eye patients has been approved in the [LOCATION_002] but not in Europe. This drug seems to affect only inflammation and tear film production, without any effect on ocular surface sensitivity or the corneal epi[INVESTIGATOR_2130]. On the other hand, experimental and clinical evidence suggests that NGF may affect all the pathogenic mechanisms of dry eye, potentially restoring ocular surface homeostasis (3). Indeed, several studies have shown that NGF is involved in the regulation of tear film production. In fact, NGF, TrkA and p75, as well as other neurotrophins (NTs) and related receptors, are expressed by [CONTACT_58195]; moreover, NGF has been quantified in human tears, indicating that NGF is basally released by [CONTACT_58196] (4,5,6). These data suggest that NGF may play a role in the maintenance of the tear film and in its alterations in drying ocular surface diseases. Specifically, considering that NGF potentially affects all the components of the ocular surface (cornea, conjunctiva, lacrimal gland, and sensory innervation), it might play an important role during dry eye disease. In line with this hypothesis: 1) NGF eye drop administration in a dog experimental model of dry eye increases tear production, conjunctival goblet cell density and corneal transparency (7, 2), an increased tear concentration of NGF has been reported in patients affected by [CONTACT_395835]√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 31 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 31 of 90  
(8;9), NGF stimulates glycoconjugate secretion by [CONTACT_58198], without affecting cell proliferation (10).  2.2. A SUMMARY OF CLINICAL DATA  rhNGF has been already studied in healthy volunteers and in different subject populations.  In the completed Phase I study in healthy volunteers (study NGF0112), a total of 58 subjects (out of 74 enrolled) were treated with single and multiple dose of different concentrations of rhNGF eye drops showing a good safety profile.  Furthermore, a Phase I/II multicenter, double-masked, vehicle controlled study to evaluate the safety and efficacy of rhNGF at 10 and 20 Œºg/mL six times a day in 174 patients with stage 2 and 3 of Neurotrophic Keratitis NK (study NGF0212) was completed in 2015 demonstrating that rhNGF was very well tolerated and effective in patients with NK. A successful confirmatory study (NGF0214) was completed in 2016 and marketing authorization for rhNGF 20 Œºg/mL eye drops has been granted by [CONTACT_395836] [ADDRESS_497669] been evaluated in a Phase I/II study in retinitis pi[INVESTIGATOR_1802] (RP) patients at the doses of 60 and 180 Œºg/mL (NGF0113), and in a phase I/II study in glaucoma at the dose of 60Œºg/mL (NGF0314). An open arm, uncontrolled study showed that 4 weeks treatment with rhNGF eye drops at 20 Œºg/mL and 4 Œºg/mL concentrations was safe and effective in improving symptoms, corneal staining and tear function in patients with severe dry eye disease as compared to baseline (NGF0213). These results prompted to the conduction of two additional phase II RCTs in patients with dry eye disease (NGF0216) and in patients with ocular discomfort symptoms following refractive surgery (NGF0116) which confirmed the favourable tolerability profile of rhNGF eye drops at a concentration of 20 Œºg/mL up to 6 times daily for 8 weeks.  In the double-masked vehicle-controlled Phase II study NGF0216 no major differences were observed in term of efficacy when comparing the two regimens (6 vs. 2 times/day) and treatment durations (8 vs. 4 weeks) in a subset of patients with similar characteristics (hyposecretive dry eye with Schirmer test <10mm/5min).  The results of these two studies in dry eye disease patients, as well as the results on reflex tear secretion obtained in the neurotrophic keratitis trials NGF0212 and NGF0214, suggest that the rhNGF may be a safe and effective treatment for patients with hyposecretive dry eye disease. In all studies rhNGF was well tolerated and the reported ocular AEs were generally transient and mostly mild and moderate in intensity during the controlled treatment period and the follow-up period. Only moderate and transient ocular AEs possibly related to rhNGF administration were reported. In the  Phase I study in healthy volunteers of Japanese ethnicity (study NGF0117) a total of 30 subjects were enrolled. 20 subjects were treated with  single dose of rhNGF (formulation containing L-methionine as excipi[INVESTIGATOR_841]) at concentration 20 Œºg/mL and a total of 10 subjects were treated with placebo. During the studyno adverse events  occurred.   Single and multiple doses of rhNGF delivered Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 32 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 32 of 90  
topi[INVESTIGATOR_395802]. No clinically important changes in ECG were observed after dosing with rhNGF. There was no apparent relationship between treatment and plasma rhNGF levels, and this study did not give any indication for an immunogenic potential of rhNGF in humans after ophthalmic treatment. 2.3. STUDY RATIONALE The data reported above, together with the evidence of rhNGF eye drop effectiveness in the treatment of patients affected by [CONTACT_317876][INVESTIGATOR_317816], make rhNGF a strong candidate for the treatment of dry eye disease (11, 12, 13). As part of the development plan, the present study was designed in order to evaluate the efficacy and safety of rhNGF eye drops 20 ¬µg/mL in patients with moderate to severe dry eye. For additional information regarding the development of rhNGF, please consult the current IB. 2.3.1. Risk assessment/benefit evaluation The study is considered a low risk interventional trial. It is conducted with a dose of medicinal product already tested and already authorized in some European countries and recently by [CONTACT_395837].  The study is conducted in severe to moderate dry eye, a disease not approved, however [ADDRESS_497670] the dose proposed in this protocol is rhNGF 20 ¬µg/mL three drops per day (both eyes), which is well below the dose approved for the treatment of NK (rhNGF 20 ¬µg/mL six drops/eye per day). Considering what is discussed above no particular safety risks are foreseen with respect to the safety profile of the marketed product (OXERVATE¬Æ 20 ¬µg/mL).  The patients with dry eye participating in this study may potentially benefit from the application of rhNGF for 28 days.   The following potential study risks were evaluated:  1) Participant well-being e.g.- risk-benefit balance - burden of study visits  2) Lifestyle requirements- Study specific procedures which carry risk -additional to standard care (es: week of run in) 3) Complexity of study procedures  4) Education, training, experience and resources of all investigator site staff in GCP and study procedures Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 33 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 33 of 90  
5) Manufacture and distribution of the product(s), storage at the study site (e.g. availability of Frezeer at the study sites).   The details will be described in the Risk Management Plan. 2.3.2. Description of the Investigational Product  The investigational medicinal product (IMP) consists of a sterile isotonic solution for ocular administration, containing rhNGF 20 Œºg/mL (containing L-methionine as excipi[INVESTIGATOR_841]) as drug substance. The matching placebo vehicle consists of a sterile isotonic solution (containing L-methionine as excipi[INVESTIGATOR_841]). Further information are given in paragraph 5. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 34 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 34 of 90  
3. OVERALL STUDY DESIGN AND INVESTIGATIONAL PLAN  3.1. STUDY OBJECTIVES  The study objective is to assess the efficacy and safety of rhNGF when administered as eye drops to patients with moderate to severe dry eye and to exploratively evaluate the preliminary efficacy data also in a group of  dry eye patients with diagnosis of Primary Sj√∂gren's Syndrome(14). 3.2. STUDY ADMINISTRATIVE STRUCTURE This study will be performed at 8-12 study centers located in the [LOCATION_003]. At each study center, the Principal Investigator (PI) will be responsible for ensuring that the investigation is conducted according to the signed Investigator agreement, the protocol, GCP guidelines, and local regulations.  The PI [INVESTIGATOR_243861], which will consist of maintaining the study file and the patient records, corresponding with the IRB, and completing the case report forms (eCRFs) and reporting SAEs within 24 hours of initial awareness.  The PI [INVESTIGATOR_395803]. If the investigator/institution retains the services of any individual or party to perform trial-related duties and functions, the investigator/institution should ensure this individual or party is qualified to perform those trial-related duties and functions and should implement procedures to ensure the integrity of the trial-related duties and functions performed and any data generated. 3.3. OVERALL STUDY DESIGN   This is a phase II, multicenter, randomized, double masked, vehicle controlled, parallel group study designed to perform dose ranging and evaluate efficacy of rhNGF eye drops at 20 ¬µg/mL concentration administered two or three times daily for 4 weeks in patients with moderate to severe dry eye. Patients will be evaluated at screening visit (day -8), baseline (day 1+2), week 2 (day 14¬±2), week 4 (day 28¬±2) or early withdrawal and week 8 (day 56¬±2), week 12 (day 84¬±4), week 16 (day 112¬±7) of follow up. During the screening (day -8) all procedures for inclusion will be performed. From the day of screening the patients will stop any kind of further treatment, except commercially available preservative free artificial tears for a period of 7 days and 9 days as maximum (day -8 to day -1+2) until the baseline visit (day 1). At the end of the wash out period (day -8 to day -1+2) , patients meeting the entry criteria for this study will be randomized 1:1:1 and treated for 4 weeks with either rhNGF eye drops 20 ¬µg/mL TID, rhNGF eye drops 20 ¬µg/mL BID and vehicle SID or vehicle TID.  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 35 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 35 of 90  
During the 4 weeks of masked treatment only the administration of IMP it is allowed. Nevertheless, if strictly needed, the patient can take  preservative free artificial tears (provided by [CONTACT_1034]). The use (n¬∞ drops/day) of preservative free artificial tears will be clearly documented in a patient‚Äôs diary and in the eCRF.   Following the completion of the double-blind treatment patients will be followed up for safety assessments for an additional [ADDRESS_497671] treatment and will be evaluated at the end of the safety follow-up period. During the safety follow-up period patients will not use further treatment except preservative free artificial tears provided by [CONTACT_395828] (morning, afternoon, evening ).  The use of preservative free artificial tears will be clearly documented in a patient‚Äôs diary and in the eCRF. The total duration of the study is 17 weeks.               Figure 1:Study duration         
Day 1 +2 
Week 4  ¬± 2 days 
Week 8  ¬± 2 days 
Week 12  ¬± 4 days 
Week 16  ¬± 7 days 
Day -8 
Screening 
Visit 1 Baseline  Randomization 
Visit 3 End of  treatment  
Visit 5 Follow up  
Visit 6 Follow up 
Follow-up Phase  
Treatment Phase 
Visit 4 Follow up 
Visit 2   
Week 2  ¬± 2 days Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 36 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 36 of 90  
3.3.1. Rationale for Selection of dose, control group and treatment schedule in the study  The dose proposed in this study (rhNGF 20 ¬µg /mL) has already been tested both in heathy volunteers for five consecutive days (NGF0112 and NGF0117) and in patients affected by [CONTACT_395838], including dry eye. rhNGF 20 ¬µg /mL (one drop in each eye six times daily for 8 weeks), was also tested in the Phase I/II of the NK studies (NGF0212 and NGF0214), dry eye (NGF0216) and in patients after cataract and refractive surgery (NGF0116). rhNGF 20 ¬µg/mL administered two times daily, demonstrated to be safe and well tolerated (NGF0213)  will also ensure the lubrification of the ocular surface in the present study where the use of artificial tears will be not allowed during the treatment period.  Higher doses of rhNGF (up to 180 ¬µg /mL) were administrated to patients with diseases of the back of the eye, such as retinitis pi[INVESTIGATOR_1802] (Study NGF0213) for up to 168 days.  The 20 Œºg/ml concentration of rhNGF is well sustained by [CONTACT_395839] a commercial formulation.  A dose regimen of [ADDRESS_497672] the minimum amount of lubrication that is compatible with symptoms‚Äô relief. A double-blind study design was adopted to minimize systematic bias. Randomization is expected to minimize patient selection bias and increase baseline comparability between treatment groups. The use of placebo control is critical to the study design for, providing an accurate estimate of the additive benefit of pharmacotherapy.   The use of the drug‚Äôs vehicle as placebo helps in making the latter as indistinguishable from the rhNGF solution. Patients with insufficient therapeutic response, tolerability issues, or worsening of symptoms may be discontinued at any time during the study. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 37 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 37 of 90  
4. SELECTION OF STUDY POPULATION  Male and female ‚â• 18 years with moderate to severe dry eye will be included. A total of 300 patients will be enrolled.  The safety and efficacy of rhNGF eye drops will be investigated also in a specific subgroup of patients with hyposecretive dry eye, i.e., patients with dry eye due to primary Sj√∂gren's syndrome (2, 14). To gain information on the safety and efficacy of rhNGF in this subgroup of patients at least sixty (60) patients with a documented diagnosis of Primary Sj√∂gren's Syndrome are out of [ADDRESS_497673] already been enrolled based on the inclusion/exclusion criteria of the previous version of the study protocol. This amendment is applied only to set a minimum prespecified number of patients with Primary Sj√∂gren's Syndrome.  The nature of the resulting statistical analysis in this subgroup of patients will be explorative. Including at least y 60 subjects with documented diagnosis of Primary Sj√∂gren's Syndrome within the total sample size (20%) will have no impact on the initial assumptioms concerning sample size for the following reasons: x The previous study (NGF0216), on which sample size assumptions have been based (see section 9.1), reports a similar prevalence of patients with Primary Sj√∂gren's Syndrome in their medical history (‚Åì25% in the FAS population). x As dry eye due to Sjogren‚Äôs syndrome is a hyposecretive form of the disease, the primary endpoint is appropriate for both the whole study population and the subgroup with Sj√∂gren's syndrome.  x As anticipated, the same patients could have already been enrolled based on the previously applied and approved inclusion/exclusion criteria.  4.1. INCLUSION CRITERIA To be eligible for inclusion into this study, each patient must fulfil the following inclusion criteria: 1. Male or female aged ‚â• 18 years 2. Patients with moderate to severe dry eye characterized by [CONTACT_58187]: a. Corneal and/or conjunctival staining with fluorescein using National Eye Institute (NEI) grading system > 3 b. SANDE questionnaire >[ADDRESS_497674] I (without anaesthesia) >2 mm <10 mm/5 minutes  d.  Tear film break-up time (TFBUT) < 10 seconds in the worse eye 3. The same eye (eligible eye) must fulfill all the above criteria Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 38 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497675] 6 months before enrolment (current use or recommended use of artificial tears for the treatment of Dry Eye) 5. Best corrected distance visual acuity (BCDVA) score of ‚â• 0.1 decimal units (20/200 Snellen value) in both eyes at the time of study enrolment  6. If a female of childbearing potential, have a negative pregnancy test  7. Only patients who satisfy all Informed Consent requirements may be included in the study. The patient and/or his/her legal representative must read, sign and date the Informed Consent document before any study-related procedures are performed. The Informed Consent form signed by [CONTACT_8097]/or legal representative must have been approved by [CONTACT_395834] 8. Patients must have the ability and willingness to comply with study procedures. 9. Primary Sj√∂gren's Syndrome Patients: x patients with a documented diagnosis of Primary Sj√∂gren's Syndrome according the American-European Consensus Group Sj√∂gren's Syndrome Criteria (Appendix 3; must meet either 4 out of 6 total criteria OR 3 out of 4 signs). Note: Subjects who are on systemic (oral) therapy for the treatment of Sj√∂gren's Syndrome must be on stable systemic treatment defined as the same treatment for the immediately prior 90 days. 4.2. EXCLUSION CRITERIA Patients who meet any of the following criteria are NOT eligible for inclusion in the study: 1. Inability to speak and understand the local language sufficiently to understand the nature of the study, to provide written informed consent, and to allow the completion of all study assessments   2. Evidence of an active ocular infection, in either eye   3. Presence of any other ocular disorder or condition requiring topi[INVESTIGATOR_395797]  4. History of severe systemic allergy or severe ocular allergy (including seasonal conjunctivitis) or chronic conjunctivitis and/or keratitis other than dry eye  5. Intraocular inflammation defined as Tyndall score >0  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 39 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497676] 5 years  7. Systemic disease not stabilized within 1 month before Screening Visit (e.g. diabetes with glycemia out of range, tyroid malfunction..) or judged by [CONTACT_317880] (e.g. current systemic infections) or with a condition incompatible with the frequent assessment required by [CONTACT_1758]  8. Patient had a serious adverse reaction or significant hypersensitivity to any drug or chemically related compounds or had a clinically significant allergy to drugs, foods, amide local anesthetics or other materials including commercial artificial tears, in particular commercial artificial tears containing carboxymethylcellulose (CMC) (in the opi[INVESTIGATOR_871])  9. Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:  a. are currently pregnant or,  b. have a positive result at the urine pregnancy test (Screening/Baseline day 1) or,  c. intend to become pregnant during the study treatment period or,  d. are breast-feeding or, e. are not willing to use highly effective birth control measures, such as: hormonal contraceptives - oral, implanted, transdermal, or injected - and/or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or IUD - during the entire course of and [ADDRESS_497677] of the study, confound the interpretation of the study results, or endanger the patient‚Äôs well-being   11. Use of topi[INVESTIGATOR_8579], topi[INVESTIGATOR_395798] [ADDRESS_497678] lenses or punctum plug use during the study (previous use not an exclusion criteria but must be discontinued at the pre-screening visit)  13. History of drug addiction or alcohol abuse  14. Any prior ocular surgery (including refractive palpebral and cataract surgery) if within 90 days before the pre-screening visit  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 40 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497679] 60 days  16. Participation in another clinical trial study at the same time as the present study 4.3. ELIGIBLE EYE Assuming that all the inclusion/exclusion criteria are met in both eyes, the worse eye (eligible eye) will be determined at the baseline visit using a stepladder approach, as follows: 1. Schirmer‚Äôs Test (since this is the primary endpoint)-Worse eye determined as eye with lower Schirmer I score. If Schirmer I score is the same in both eyes, worse eye will be determined by [CONTACT_317881] (cornea+conjunctival staining). 2. NEI score (cornea+conjunctival staining).  If all of the above are identical, determination of the worse eye will be based on the Investigator‚Äôs judgement, then simply use the right eye as the eligible eye. 4.4. ASSIGNMENT OF PATIENT NUMBER Each patient who provides written consent to participate in this study will be assigned a unique 5-digit PID number (e.g. 01-001) consisting of a 2-digit study center number followed by [CONTACT_941] 3-digit screening number assigned sequentially by [CONTACT_180443], from 001 to 300.  4.5. RANDOMISATION Eligible patients will be randomized in a 1:1:1 ratio to either rhNGF eye drops solution 20 ¬µg/ml TID (‚Åì100 patients) or rhNGF  eye drops solution 20 ¬µg/ml BID plus vehicle eye drop solution SID (‚Åì100 patients) or vehicle eye drop solution TID (‚Åì100patients). Randomization will be stratified according to absence/presence of a documented diagnosis of Primary Sj√∂gren's Syndrome to ensure balanced assignment across treatment groups. Each randomized patient will be allocated with randomization number, according to the stratified randomization list. Drop outs after randomization will not be replaced. Randomization list as well as associated kit numbers will be be generated by a member of Syneos Health Biostatistics department, not involved in the conduct of the study.  Patients will be assigned to treatment in numerical order. A tear-off label from the kit box, with the kit number, will be attached to the investigational product dispensing log.  The enrollment of patients will be scheduled in order to assure an inclusion of approximately 240 patients without Primary Sj√∂gren's Syndrome diagnosis and at least 60 patients  with Primary Sj√∂gren's Syndrome. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 41 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 41 of 90  
4.6. MASKING The identity of the treatments will remain unknown to the patient, Investigator, site staff and Sponsor‚Äôs clinical research personnel until the study is unmasked for the final statistical analysis (after data base lock) except in case of specific events that will require unmasking of the patient. The vials containing rhNGF (20 ¬µg/ml) or vehicle will be identical in appearance, and the contents of the vials will be indistinguishable. All staff directly involved in the analysis of study results will remain masked to treatment assignments while the study is in progress. A list of sequential kit numbers will be generated by a member of the Syneos Health not involved in the conduct of the study. Each kit number will be randomly associated with a treatment group. Patients will be assigned to treatment in numerical order. A tear-off label from the kit box, with the kit number, will be attached to the investigational product dispensing log. The investigator will be provided with an access, password protected, to the RAVE Randomization and Trial Supply Management system (RAVE RSTM) so only in case of a medical emergency the Investigator can open the treatment allocation for a specific patient.  Besides also Domp√© Pharmacovigilance contact [CONTACT_395829], password protected, to the RAVE Randomization and Trial Supply Management system (RAVE RSTM) so if required by [CONTACT_395830] a specific Patient.  In the event of a medical emergency where the knowledge of patient treatment is required to provide the patient with appropriate care, Investigators will have the possibility to unmask the treatment assignment for a specific patient. The Investigators are encouraged to contact [CONTACT_395840]. If the Investigator becomes unmasked for any reason, this information will be recorded on source data and in the eCRF of the study, specifying the date and the reason.   Unmasking events will be recorded and reported in the final study report.  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 42 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497680] (NIMP) TEST PRODUCT  NIMP  Blink¬Æ Tears  Pharmaceutical form  Eye Drops Solution Administration  One drop of Blink¬Æ Tears will be instilled in both eyes during the 4 weeks of masked treatment, only if strictly needed by [CONTACT_102].  One drop of Blink¬Æ Tears will be instilled in both eye TID (morning, afternoon and evening) during the [ADDRESS_497681] document in the patient‚Äôs diary the n¬∞ of additional drops administered for each eye. Administration route    Ocular         5.1.2. Presentation of Investigational Medicinal Product  TEST PRODUCT  IMP Recombinant human nerve growth factor (rhNGF), containing L-methionine as excipi[INVESTIGATOR_841] (20 Œºg/mL) and/or Placebo vehicle, containing L-methionine as excipi[INVESTIGATOR_841] (Vehicle vials).  Manufacturer active substance  Domp√© Farmaceutici S.p.A., Italy Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 43 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497682] and reference will be instilled in both eyes according to the following scheme:  Group 1: one drop of rhNGF 20 ¬µg/ml will be instilled in both eyes three times daily (every 6-8 hours, e.g. 7:00 am, 02:00 pm; 09:00 pm).  Group 2: one drop of rhNGF 20 ¬µg/ml will be instilled in both eyes two times daily plus one drop (40 ¬µL) of vehicle will be instilled in both eyes once daily (every 6-8 hours, e.g. 7:00 am, 02:00 pm; 09:00 pm). NB: rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon.  Group 3: vehicle eye one drop will be instilled in both eyes      three times daily (every 6-8 hours, e.g. 7:00 am, 02:00 pm; 09:00 pm).  Administration route    Ocular             
 Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 44 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497683] monthly box, containing 4 weekly boxes, containing 7 daily boxes. Each daily box contains three marked vials (e.g. 1- Morning, 2- Afternoon and 3- Evening) of frozen IMP solutions (-20 ¬± 5¬∞C) containing:    ‚Ä¢ rhNGF, at concentrations of 20 ¬µg /mL, and/or  ‚Ä¢ vehicle (placebo). Together with the IMP monthly box, the patients will be provided with a sufficient number of pi[INVESTIGATOR_395799]. Pi[INVESTIGATOR_395804]. The pi[INVESTIGATOR_395805] a connecting device with dual connections: one end for the pi[INVESTIGATOR_395806].  The patient will need to:  1. Put the adaptor on the top of the vial (after removing the plastic seal) by [CONTACT_21173][INVESTIGATOR_395807] 2. Put the pi[INVESTIGATOR_395808] 3. Draw the solution contained in the vial with the pi[INVESTIGATOR_395809] 4. Remove the pi[INVESTIGATOR_317821] a dropper to administer one drop of IMP into each eye. 5.2.1. Labeling  [IP_ADDRESS]. NIMP Secondary packaging, single pane label for single vial (Blink¬Æ Tears) Line No. Text 1 NGF0118 2 Domp√© farmaceutici s.p.a 3 Blink¬Æ Tears  4 Unique Patient N¬∞ ¬Ö¬Ö-¬Ö¬Ö¬Ö 5 Eye drops solution 6 To be used ONLY during the masked treatment* 7 FOR OCULAR USE ONLY- LEAFLET: information for user 8 For clinical trial use only * the patient can use the Blink ¬Æ Tears during the masked treatment only if strictly needed according the product leaflet Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 45 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 45 of 90  
 Line No. Text 1 NGF0118 2 Domp√© farmaceutici s.p.a 3 Blink¬Æ Tears  4 Unique Patient N¬∞ ¬Ö¬Ö-¬Ö¬Ö¬Ö 5 Eye drops solution 6 To be used ONLY during the Follow up period* 7 Morning/afternoon/evening  8 FOR OCULAR USE ONLY- LEAFLET: information for user 9 For clinical trial use only  * the patient must use the Blink ¬Æ Tears during the Follow up period, three times daily (morning, afternoon and evening)   [IP_ADDRESS]. Primary packaging, single pane label for single vial (rh-NGF or Vehicle)  Line No. Text Comments 1 NGF0118   2 Domp√© farmaceutici s.p.a  3 rhNGF 20 ¬µg /ml and/or Vehicle  4 Administration eye: RIGHT and LEFT   6 Eye drops solution   7 Batch: <vvvv>   Codified batch 8 Kit XXXX * Format of kit no.: "XXXX‚Äù  10 Morning/afternoon/evening**  13 CAUTION: New Drug-Limited by [CONTACT_4496] (or [LOCATION_002]) law to investigational use   * The number of KIT will be reported according to the randomization list that will be generated  ** Each vial will be a marked vial, one for each administration: morning, afternoon, evening. The vial will be a coloured vial one colour for each administration as follow: White-morning, yellow-afternoon and light blu-evening. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 46 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 46 of 90  
[IP_ADDRESS]. Secondary packaging, single pane label for daily box (3 marked vials of rh-NGF and/or Vehicle)  Line No. Text Comments 1 NGF0118   2 Domp√© farmaceutici s.p.a  3 rhNGF 20 ¬µg /ml and/or Vehicle  4 Administration eye: RIGHT and LEFT   6 Eye drops solution   7 Batch: <vvvv>   Codified batch 8 Kit XXXX * Format of kit no.: "XXXX‚Äù  9 Store in a refrigerator at 2-8 ¬∞C (36¬∞F to 46¬∞F) or at room temperature not exceeding 12 hours  10 Do not shake  11 Keep out of reach of children  12 CAUTION: New Drug-Limited by [CONTACT_4496] (or [LOCATION_002]) law to investigational use   * The number of KIT will be reported according to the randomization list that will be generated    Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 47 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 47 of 90  
 [IP_ADDRESS]. Tertiary packaging, single panel label for weekly box (7 daily boxes)  Line No. Text Comments 1 NGF0118   2 Domp√© farmaceutici s.p.a  3 rhNGF 20 ¬µg /ml and/or Vehicle  4 Administration eye: RIGHT and LEFT   6 Eye drops solution  7 Batch: <vvvv>   Codified batch 8 Kit XXXX * Format of kit no.: "XXXX‚Äù  9 Store in a refrigerator at 2-8 ¬∞C (36¬∞F to 46¬∞F) for 7 days  10 Do not shake  11 Keep out of  reach of children  12 CAUTION: New Drug-Limited by [CONTACT_4496] (or [LOCATION_002]) law to investigational use   * The number of KIT will be reported according to the randomization list that will be generated.                    Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 48 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 48 of 90  
[IP_ADDRESS]. Quaternary packaging, tear- off label  monthly box (4 weekly boxes, 28 days of treatment Line No. Text Comments Tear Off part of the label 1 Protocol no.: NGF0118   To be enclosed 2 Sponsor: Domp√© farmaceutici s.p.a, Via Santa Lucia, 6 - [ZIP_CODE] Milano, Italy  To be enclosed 3 rhNGF 20 ¬µg /ml and/or Vehicle  To be enclosed 4 Eye drops solution   5 Contains 4 weekly boxes. One of each contains 7 daily boxes that contains 3 marked vials   6 Directions for use: refer to dosing instructions   4 Administration eye: RIGHT and LEFT  The administration will be according to the randomization list: Active for group 1; Active/Placebo for group 2 and Placebo for group 3.  To be enclosed 7 Batch: <vvvv>   Codified batch To be enclosed 8 Kit XXXX  Format of kit no.: "XXXX"   To be enclosed 9  Unique Patient N¬∞ ¬Ö¬Ö-¬Ö¬Ö¬Ö  To be enclosed  10 Store in a freezer at -20¬∞C +/- 5¬∞ C    11 Do not shake   12 Keep out of reach of children   13 For clinical trial use only   14 CAUTION: New Drug-Limited by [CONTACT_4496] (or [LOCATION_002]) law to investigational use    5.3.  STORAGE AND HANDLING OF IMP The Pharmacist and/or Investigator will be responsible for receipt, proper storage, and usage of study drug, as well as for the IMP distribution, collection of used and unused vials and final disposal of the remaining IMP.  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 49 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497684] be stored at -20 ¬± 5 ¬∞C at the investigational sites, in an appropriate locked room accessible only to the pharmacist, the Investigator, or a duly designated person.  A temperature probe and data logger will accompany the drug on shipment. It is essential that the investigational sites will verify the temperature excursion during shipment vs. the acceptable storage conditions, in order to identify potential stability concerns during shipment. These must be immediately communicated to the Sponsor that will decide upon appropriate actions to be taken. The IMP will be stored in a locked place, sheltered from light. The vials will be not shaken since agitation of vials may cause foaming and/or particle formation.  On Day 1 (baseline visit), the study personnel will give to the patient the monthly boxes containing the study medications Patient should bring the study medication, one monthly box, at home as soon as possible and immediately store it in a freezer at -20 ¬± 5 ¬∞C. The weekly box must be kept at 2-8¬∞C for 7 days protected from light; the daily box can be kept at room temperature,  before the patient will use the single vial for each instillation (both eyes) as long as 12 hours are not exceeded. Agitation of vials may cause foaming and/or particle formation. Drug preparation and administration instructions will be provided separately to the site and to the patients.   Together with the IMP monthly box, the patient will also receive a separate kit of vial adapters (one per vial), pi[INVESTIGATOR_6343] (1 per vial) and disinfectant wipes (1 per vial). IMP eye drops solution instruction will be provided to patients.  Patients will use one vial to instill one drop in both eyes (group 1: rhNGF TID; group 2: rhNGF BID and vehicle SID; group 3: vehicle TID) between 7 AM and 9 PM (every 6-8 hours) for [ADDRESS_497685] given authorization for its continued use. The IMP supplies are to be used only in accordance with this protocol. The Investigator will not use any drug samples for other purposes (e.g., treating patients or deviating from the protocol with regard to dose regimen, duration of treatment, etc.). Under no circumstances will the Investigator give any drug samples to a third party. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 50 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497686] administration is to be applied by [CONTACT_395841]. 5.4.2. Dose regimen In all patients both eyes will be treated for a period of 4 weeks.  The dosing scheme of the different study groups is summarized below:  Group 1: one drop of rhNGF 20 ¬µg/ml will be instilled in both eyes three times daily (every 6-8 hours, e.g. 7:00 am, 02:00 pm; 09:00 pm).  Group 2: one drop of rhNGF 20 ¬µg/ml will be instilled in both eyes two times daily plus one drop (40 ¬µL) of vehicle will be instilled in both eyes once daily (every 6-8 hours, e.g. 7:00 am, 02:00 pm; 09:00 pm). NB: rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon.  Group 3: vehicle eye one drop will be instilled in both eyes  three times daily (every 6-8 hours, e.g. 7:00 am, 02:00 pm; 09:00 pm).  During the 4 weeks of masked treatment only the administration of IMP  is allowed. Nevertheless, if strictly needed, the patient can take a preservative free artificial tears (provided by [CONTACT_1034]). The use (n¬∞ drops/day) of preservative free artificial tears will be clearly documented in a patient‚Äôs diary and in the eCRF.  Both the patients and the investigator will be masked to the study treatment. Information about the  study drug administration, and comments, will be recorded on the appropriate page of the eCRF.  5.5. ACCOUNTABILITY OF THE IMP The Pharmacist and/or Investigator will confirm the receipt of the IMP supply in writing by [CONTACT_58206]. At the week 4 (end of treatment visit) the patient will return the used or unused study boxes/vials to the Investigator.  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 51 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497687] and/or Investigator will keep a cumulative inventory and dispensing records, and will maintain all supplies under adequate security.  An accurate drug disposition record will be kept, specifying the date and amount dispensed to each patient.  Adequate record of receipt and use or loss of drug will be retained. This inventory record must be available for inspection by [CONTACT_58207]. Copi[INVESTIGATOR_395810]. At the scheduled visit, the patient diary should be reviewed by [CONTACT_395842]. Missing information should not be provided during the diary check but reported as missing. At the conclusion of the study, and during the course of the study, the Investigator will complete the drug accountability forms. Partially used or unused study drug boxes will be verified by [CONTACT_395843]. 5.6. CONCOMITANT MEDICATION  As a general rule, no ophthalmic medication other than study drug will be given to the patient from the screening day until all of the final study evaluations have been completed, except for preservative free artificial tears.  The preservative free artificial tears will be provided by [CONTACT_395844]: 1) During the 4 weeks of masked treatment, only if strictly needed, the patient will instill one drop in both eyes. 2) During the 12 weeks of Follow up period one drop will be instilled in both eyes TID (morning, afternoon and evening).  The use (n¬∞ drops/day) of preservative free artificial tears will be clearly documented in the patient‚Äôs diary and eCRF.   All medications (including over-the-counter drugs, herbal products, vitamins, and antacids) taken within [ADDRESS_497688] name (if a combination drug product) and spelled correctly. The dose, unit, frequency, route of administration, start date, discontinuation date, and indication should also be recorded. For medications administered only one time, the frequency column may reflect "once." Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 52 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497689] visit (FPFV) is defined as the 1st visit performed at one of the clinical centers by [CONTACT_941] 1st screened patient. The last patient, last visit (LPLV) is defined as the last visit performed at one of the clinical centers by [CONTACT_58211] (i.e., the last visit foreseen by [CONTACT_4690]), independently of whether the patient completed or withdrew from the study. The First Patient In (FPI) is defined as the first randomized patient at one of the clinical centers.  Patients will be evaluated according to the following scheme:  Interventional phase ¬æ Screening visit (day -8),  ¬æ Baseline (day 1+2),  ¬æ Week 2 (day 14r2 ), ¬æ Week 4 (day 28r2 ) or early exit  Follow up visits ¬æ Week 8 (day 56¬±2),  ¬æ Week 12 (day 84r4)  ¬æ Week 16 (day 112r7)   The schedule of study procedures and assessments is tabulated by [CONTACT_395845] ¬ß 2.0.  The descriptions of the procedures to be performed at each visit are provided below.   Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 53 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 53 of 90  
6.1. SCREENING AND RANDOMIZATION VISITS During the screening visit (day -8) all procedures for inclusion will be performed. From the day of screening the patients will stop any kind of further ophthalmic treatment, until all of the final study evaluations have been completed, except preservative free artificial tears (wash out period from day -8 to day -1 +2). The wash out period should not be less than 7 days and more than 9 days.  At the end of the screening period, patients meeting the entry criteria for this study will be randomized 1:1:1 and treated for 4 weeks with either rhNGF eye drops 20 ¬µg/mL TID, rhNGF eye drops 20 ¬µg/mL BID and vehicle SID or vehicle TID.  Day Procedures/Assessments Screening visit  Day -8 The following procedures will be performed (order below is mandatory): ¬æ Explanation to the patient of study aims, procedures and possible risks ¬æ Informed consent signature ¬æ Screening number allocation  ¬æ Patient eligibility: Inclusion/exclusion criteria evaluation ¬æ Pregnancy test for female patients of childbirth potential ¬æ Demographic data ¬æ Ocular and systemic medical history ¬æ Previous ocular and systemic medications (prior to start the study) ¬æ Ocular examination of both eyes: x Assessment by [CONTACT_58212] x Assessment by [CONTACT_317891] x Assessment by [CONTACT_28973]-5D-3L questionnaire x Assessment of best corrected distance visual acuity (BCDVA) x External Ocular Examination x Schirmer test  I (without anesthesia)  x Slit-lamp examination (SLE) to assess the eyelid (Meibomian glands), eyelid (erythema), eyelid (edema), lashes, conjunctiva erythema, lens, iris, anterior chamber, corneal horizontal diameter x TFBUT x Ocular surface staining (NEI score - corneal and conjunctival fluorescein staining) ¬æ AE collection  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 54 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 54 of 90  
 Day Procedures/Assessments Visit 1 Baseline Day 1 +2  The following procedures will be performed (order below is mandatory):  ¬æ Pregnancy test for female patients of childbirth potential ¬æ Previous ocular and systemic medications (prior to start the treatment) ¬æ Ocular examination of both eyes: x Assessment by [CONTACT_58212] x Assessment by [CONTACT_317891] x Assessment by [CONTACT_28973]-5D-3L questionnaire x Assessment of best corrected distance visual acuity (BCDVA) x External Ocular Examination x Schirmer test  I (without anesthesia)  x Slit-lamp examination (SLE) to assess the eyelid (Meibomian glands), eyelid (erythema), eyelid (edema), lashes, conjunctiva erythema, lens, iris, anterior chamber, corneal horizontal diameter x TFBUT x Ocular surface staining (NEI score ‚Äì corneal and conjunctival fluorescein staining  ) x Schirmer test II (with anesthesia) x Laser scanning confocal microscopy to assess goblet cells density (only selected sites)  x Corneal endothelium and stroma evaluation (only the sites having a confocal microscope will do this type of evaluation)  ¬æ Patient eligibility: Inclusion/exclusion criteria evaluation ¬æ Randomization ¬æ Study drug dispensation ¬æ Preservative free artificial tears dispensation  ¬æ AE collection  The Investigator will dispense to the patients their monthly box containing the study drug for the following 4 weeks  together with an adequate number of adapters and pi[INVESTIGATOR_6343]. The Investigator will dispense to the patients the preservative free artificial tears to be used only if strictly needed by [CONTACT_102] (the patient must follow the instruction in the product leaflet ). After completing baseline evaluation patients will be administered, by [CONTACT_976], with the study treatment as per instructions, and will self-administer at home the subsequent doses. Patients will return to the clinical site on Day 14 (¬±2)  (Week 2, visit 2). The patients will be instructed to enter  information of self-administration (if the administration has been occur per eye), AE occurrence,  concomitant medication intake and possible self-administration of preservative free artificial tears into the diary. The diary will be given from the PI [INVESTIGATOR_317824].   Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 55 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497690] two weeks of treatment the patient will undergo  a medical assessment during the visit 2 (week 2). Following the completion of the double-blind treatment (visit 3, week 4), patients will be followed up for safety assessments for an additional [ADDRESS_497691] treatment and will be evaluated at the end of the safety follow-up period. During the safety follow-up period patients will not use further ophthalmic treatment except preservative free artificial tears, provided by [CONTACT_2728], one drop instilled in both eyes three times daily (morning, afternoon and evening). The patient, only if strictly needed, can administer additional drops and must document in the patient‚Äôs diary the n¬∞ of additional drops administered for each eye.   Day Procedures/Assessments At home Days 0-14 ¬±2 ¬æ Self-administration at home of the IMP, three times daily every 6-8 h for both eyes (diary) ¬æ Recording any new or changes in concomitant medications (diary) ¬æ Recording any unusual medical conditions  - AE monitoring (diary) ¬æ Recording possible use of preservative free artificial tears (diary). Data will be recorded by [CONTACT_58213]‚Äôs diary. Visiti 2 Week 2 Day 14¬±2 The following procedures will be performed (order below is mandatory):  ¬æ Ocular examination of both eyes: x Assessment by [CONTACT_58212] x Assessment of best corrected distance visual acuity (BCDVA) x External Ocular Examination x Schirmer test  I (without anesthesia)  x Slit-lamp examination (SLE) to assess the Eyelid - Meibomian glands, Eyelid ‚Äì Erythema, Eyelid - Edema Lashes, Conjunctiva Erythema, Lens, Iris, Anterior Chamber, Corneal Horizontal Diameter x Tear Film Break-up Time (TFBUT) x Ocular surface staining (NEI score - corneal and conjunctival fluorescein staining) ¬æ Concomitant ocular and systemic medications ¬æ Frequency of patient‚Äôs  artificial tear use during first 2  weeks of treatmen (to be reported in eCRF) ¬æ AE monitoring  During the visit 2, week 2, the patient must bring the diary assigned during the previous visit. The PI [INVESTIGATOR_1660] a delegate must check if patient has correctly complete the diary. If not, the site staff must retrain the patient.  At completion of the assessment the patient will be discharged and will be asked to return for the end of treatment visit on day 28¬±2 (Visit 3 week 4).  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 56 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 56 of 90  
 Day Procedures/Assessments At home  Days 14 ¬±2‚Äì 28 ¬± 2 ¬æ Self-administration at home of the IMP, three times daily every 6-8 h for both eyes (diary) ¬æ Recording any new or changes in concomitant medications (diary) ¬æ Recording any unusual medical conditions  - AE monitoring (diary) ¬æ Recording possible use of preservative free artificial tears (diary). Data will be recorded by [CONTACT_58214]‚Äôs diary. Visit 3  week 4  Day 28¬±2    The following procedures will be performed (the below order is  mandatory):  ¬æ Ocular examination of both eyes: x Assessment by [CONTACT_58212] x Assessment by [CONTACT_317891] x Assessment by [CONTACT_28973]-5D-3L questionnaire x Assessment by [CONTACT_395846] x Assessment of best corrected distance visual acuity (BCDVA) x External Ocular Examination x Schirmer test  I (without anesthesia)  x Slit-lamp examination (SLE) to assess the Eyelid - Meibomian glands, Eyelid ‚Äì Erythema, Eyelid - Edema Lashes, Conjunctiva Erythema, Lens, Iris, Anterior Chamber, Corneal Horizontal Diameter x Tear Film Break-up Time (TFBUT) x Ocular surface staining (NEI score - corneal and conjunctival fluorescein staining) x Schirmer test II (with anesthesia) x Laser scanning confocal microscopy to assess goblet cells density(only selected sites)  x Corneal endothelium and stroma evaluation (only the sites having a confocal microscope will do this type of evaluation) ¬æ Assessment of compliance to treatment (from patient diary and IMP reconciliation from returned weekly boxes) ¬æ Concomitant ocular and systemic medications ¬æ Frequency of patient‚Äôs artificial tear use during the last 2  weeks of treatment  (to be reported in eCRF). ¬æ AE monitoring  During visit 3, week 4, PI [INVESTIGATOR_395811]‚Äôs diary concerning the treatment period.  At completion of the assessment the patient will be discharged and will be asked to return for the follow up visit on day 56¬±2 (Visit 4 week 8). The Investigator will dispense to the patients the preservative free artificial tears (Blink ¬Æ Tears) to be self-administered three times daily, one drop in both eyes during the first 4 weeks of Follow up. The PI [INVESTIGATOR_395812], only if strictly needed, they can administer an additional numbers of drops of Blink ¬Æ Tears, by [CONTACT_395847]‚Äôs diary.   Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 57 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 57 of 90  
 Day Procedures/Assessments At home Days 28 ¬±2‚Äì 56 ¬± 4 ¬æ Recording any new or changes in concomitant medications (diary) ¬æ Recording any unusual medical conditions  - AE monitoring (diary) ¬æ Artificial tears use during 4 weeks of FU (diary) Data will be recorded by [CONTACT_58214]‚Äôs diary. Visit 4 Follow up week 8  Day 56¬± 4 The following procedures will be performed (the below order is  mandatory):  ¬æ Ocular examination of both eyes: x Assessment by [CONTACT_58212] x Assessment by [CONTACT_317891] x Assessment by [CONTACT_28973]-5D-3L questionnaire x Assessment by [CONTACT_395846] x Assessment of best corrected distance visual acuity (BCDVA) x External Ocular Examination x Schirmer test  I (without anesthesia)  x Slit-lamp examination (SLE) to assess the Eyelid - Meibomian glands, Eyelid ‚Äì Erythema, Eyelid - Edema Lashes, Conjunctiva Erythema, Lens, Iris, Anterior Chamber, Corneal Horizontal Diameter x Tear Film Break-up Time (TFBUT) ¬æ Ocular surface staining (NEI score - corneal and conjunctival fluorescein staining) ¬æ Concomitant ocular and systemic medications ¬æ Frequency of patient‚Äôs artificial tear use during 4 weeks of FU (to be reported in eCRF). ¬æ AE monitoring  During visit 4, week 8, PI [INVESTIGATOR_395813]‚Äôs diary concerning the first follow up period. The Investigator will dispense to the patient the preservative free artificial tears (Blink ¬Æ Tears) to be self-administered three times daily, one drop in both eye during the second 4 weeks of Follow up. The PI [INVESTIGATOR_395812], only if strictly needed, they can administer an additional numbers of drops of Blink ¬Æ Tears, by [CONTACT_395847]‚Äôs diary.   At home  Days 56 ¬±4‚Äì 84 ¬± 4 ¬æ Recording any new or changes in concomitant medications (diary) ¬æ Recording any unusual medical conditions  - AE monitoring (diary) ¬æ Artificial tears use during 4 weeks of FU (diary) Data will be recorded by [CONTACT_58214]‚Äôs diary. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 58 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 58 of 90  
 Day Procedures/Assessments Visit 5 Follow up week 12   Day 84 ¬± 4  The following procedures will be performed (the below order is  mandatory):  ¬æ Ocular examination of both eyes: x Assessment by [CONTACT_58212] x Assessment by [CONTACT_317891] x Assessment by [CONTACT_28973]-5D-3L questionnaire x Assessment by [CONTACT_395846] x Assessment of best corrected distance visual acuity (BCDVA) x External Ocular Examination x Schirmer test  I (without anesthesia)  x Slit-lamp examination (SLE) to assess the Eyelid - Meibomian glands, Eyelid ‚Äì Erythema, Eyelid - Edema Lashes, Conjunctiva Erythema, Lens, Iris, Anterior Chamber, Corneal Horizontal Diameter x Tear Film Break-up Time (TFBUT) ¬æ Ocular surface staining (NEI score - corneal and conjunctival fluoresce instaining) ¬æ Concomitant ocular and systemic medications ¬æ Frequency of patient‚Äôs artificial tear use during 4 weeks of FU (to be reported in eCRF). ¬æ AE monitoring  During visit 5, week 12, PI [INVESTIGATOR_395814]‚Äôs diary concerning the second follow up period. The Investigator will dispense to the patient the preservative free artificial tears (Blink ¬Æ Tears) to be self-administered three times daily, one drop in both eye during the last weeks of Follow up. The PI [INVESTIGATOR_395812], only if strictly needed, they can administer an additional numbers of drops of Blink ¬Æ Tears, by [CONTACT_395847]‚Äôs diary.  At home  Days 84 ¬±4‚Äì 112 ¬± 7 ¬æ Recording any new or changes in concomitant medications (diary) ¬æ Recording any unusual medical conditions  - AE monitoring (diary) ¬æ Artificial tears use during 4 weeks of FU (diary) Data will be recorded by [CONTACT_58214]‚Äôs diary. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 59 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 59 of 90  
 Day Procedures/Assessments Visit 6 Follow up week 16 Final visit or early termination visit (ETV) Day 112 ¬± 7 The final visit is defined as the visit performed 84 ¬± [ADDRESS_497692] IMP administration (i.e., at day 112 ¬± 7). In case of premature study discontinuation, patients will undergo an early termination visit (ETV or end of study EOS as per eCRF).  The following procedures will be performed (the below order is  mandatory):  ¬æ Pregnancy test for female patients of childbirth potential ¬æ Ocular examination of both eyes: x Assessment by [CONTACT_58212] x Assessment by [CONTACT_317891] x Assessment by [CONTACT_28973]-5D-3L questionnaire x Assessment by [CONTACT_395846] x Assessment of best corrected distance visual acuity (BCDVA) x External Ocular Examination x Schirmer test  I (without anesthesia) x Slit-lamp examination (SLE) to assess the Eyelid - Meibomian glands, Eyelid ‚Äì Erythema, Eyelid - Edema Lashes, Conjunctiva Erythema, Lens, Iris, Anterior Chamber, Corneal Horizontal Diameter x Tear Film Break-up Time (TFBUT) x Ocular surface staining (NEI score - corneal and conjunctival fluorescein staining) x Schirmer test  II (with anesthesia) x Laser scanning confocal microscopy to assess goblet cells density (only selected sites)  x Corneal endothelium and stroma evaluation (only the sites having  a confocal microscope will do this type of evaluation) ¬æ Concomitant ocular and systemic medication ¬æ Frequency of patient‚Äôs artificial tear use during 4 weeks of FU (to be reported in eCRF) ¬æ AE monitoring  During visit 6, week 16, PI [INVESTIGATOR_395815]‚Äôs diary concerning the third follow up period.         Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 60 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 60 of 90  
6.3. EARLY WITHDRAWAL FROM THERAPY OR ASSESSMENT 6.3.1. Primary Reason For Discontinuation From The Study A premature discontinuation will occur when a patient who signed the ICF ceases participation in the study, regardless of circumstances, before the completion of the study protocol procedures. Patients can be prematurely discontinued from the study for one of the following reasons:   ¬æ Adverse event (AE): Any significant AE that, in the opi[INVESTIGATOR_317831],  is not compatible with study continuation. ¬æ Disease progression or worsening, that according to the opi[INVESTIGATOR_395816].. ¬æ Death. ¬æ Lost to follow-up (Every effort must be made to contact [CONTACT_102]; a registered letter must be sent). ¬æ Non-compliance with study drug: an indication that a patient has not agreed with or followed the instructions related to the study medication. ¬æ Physician decision: a position, opi[INVESTIGATOR_58179] a physician with reference to the patient. ¬æ Severe Protocol violation: an event or decision that stands in contrast to the guidelines set out by [CONTACT_760]. ¬æ Study terminated by [CONTACT_1034]: an indication that a clinical study was stopped by [CONTACT_2728]. ¬æ Withdrawal of consent: study discontinuation requested by a patient for whatever reason. ¬æ Other reasons, such as administrative reasons or pregnancy.   Before removal, each case should first be discussed with Domp√© farmaceutici s.p.a. The reasons for premature discontinuation from the study will be reflected on the Study Termination Record of the eCRF. Unless the patient has withdrawn consent, the follow up visit assessments should be performed as detailed in ¬ß 6.  The investigator should advise patients that prematurely discontinue on any therapi[INVESTIGATOR_395817]√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 61 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 61 of 90  
6.3.2. Discontinuation procedures For any patient discontinuing the study following randomization, the Investigator will:   ¬æ ask the patient to undergo, as far as possible, a final medical visit (ETV) to examine the patient's health conditions. This examination will verify that all values tested at screening have remained within a clinically acceptable range (i.e., not clinically significant changes compared to screening). ¬æ arrange for alternative medical care of the withdrawn patient, if necessary. ¬æ report in the eCRF date and time of the last dose administration, and date and primary reason of study discontinuation. ¬æ record in the eCRF any follow-up if the patient is withdrawn for an AE. AE‚Äôs should be followed until resolution.   6.3.3. Replacement procedure Patients in this study who prematurely discontinue treatment will not be replaced.  It will be documented whether or not each patient completed the clinical study. If, for a patient, study treatment or observations are discontinued, the primary reason for discontinuation will be recorded.  6.4. END OF STUDY Patients completing the double-blind treatment (Visits 1 Baseline to Visit 6 Follow up) will be considered completers.  For the purpose of this trial, the End of Study is defined as the date of the last visit of the last patient or upon completion of any follow-up procedure described in the protocol. The Investigator and the Sponsor have the right to discontinue the study at any time for reasonable medical and/or administrative reasons. As far as possible, this should occur after mutual consultation. Reasons for discontinuation have to be documented appropriately. In this event, no further patients will receive doses of the study drugs, and patients already having received a dose of study drug will not receive any further doses of the study IMP but will undergo all safety assessments scheduled after the last dose of study drug, up to an including the end of study examination. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 62 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 62 of 90  
7. ENDPOINTS 7.1. STUDY ENDPOINTS The study objective is to assess the efficacy and safety of rhNGF when administered as eye drops to patients with moderate to severe dry eye. Evaluation of the clinical efficacy and safety during and at the end of treatment with rhNG, will be performed on the basis of the following assessments at each time point. Evaluations will be performed on day -8 (screening), day 1+2 (visit baseline), day 14¬±2 (week 2), day 28¬±2   (week 4 End of treatment), day 56¬±4 (week 8 Visit 4 FU), day 84¬±4 (week 12 Visit 5 FU), day 112¬±7 (week 16 Visit 6 FU), according to the schedule of evaluation (¬ß 2) 7.1.1. Primary endpoint x Change from baseline in Schirmer test I (without anesthesia) Vs week 4. 7.1.2. Secondary endpoints x Change from baseline in Symptoms questionnaire (SANDE) scores for severity and frequency assessed at 4 weeks of treatment; x Change from baseline in Schirmer II test (with anesthesia) Vs week 4; x Change from baseline in Corneal and conjunctiva vital staining with fluorescein (National Eye Institute [NEI] scales) Vs week 4; x Change from baseline in Tear Film Break up time (TFBUT) Vs week 4; x Number of patients who experienced a worsening in symptom scores (SANDE) and/or NEI score >= 50% assessed at week 4; x Quality of life (Impact of Dry Eye on Everyday Life (IDEEL) questionnaire;  x Patient global Impression of change (PGIC); x  EQ-5D-3L. 7.1.3. Exploratory endpoint x Correlation between sign and symptoms scores; x Proportion and frequency of preservative free artificial tears use (n¬∞ drops/day) during the treatment period; x Frequency of preservative free artificial tears use (n¬∞ drops/day) during the follow up period. x Change from baseline in Schirmer test I (without anesthesia) Vs week 2; x Change from baseline in Symptoms questionnaire (SANDE) scores for severity and frequency assessed at 2 weeks of treatment ; Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 63 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 63 of 90  
x Change from baseline in Corneal and conjunctiva vital staining with fluorescein (National Eye Institute [NEI] scales) Vs week 2; x Change from baseline in Tear Film Break up time (TFBUT) Vs week 2; x Number of patients who experienced a worsening in symptom scores (SANDE) and/or NEI score >= 50% assessed at week 2; x Change from baseline in goblet cells density Vs week 4 7.1.4. Safety endpoint x Incidence and frequency of Treatment-emergent adverse events (TEAEs), assessed throughout the study. 7.1.5. Stratification according to absence /presence of Primary Sj√∂gren's Syndrome x The primary, secondary, explorative and safety endpoints (see 7.1.1, .7.1.2 7.1.3 & 7.1.4) will be also evaluated within each stratification subgroup (absence/presence of Primary Sj√∂gren's Syndrome).. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 64 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 64 of 90  
8. EVALUATION OF ADVERSE EVENTS AND SAFETY INFORMATION 8.1. DEFINITIONS  Adverse Event An Adverse Event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.  Adverse Drug Reaction  An Adverse Drug Reaction (ADR) is defined as any noxious and unintended response to a medicinal product related to any dose. Any responses to a medicinal product means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility, i.e., the relationship cannot be ruled out. The definition covers also medication errors and uses outside what is foreseen in the protocol, including misuse and abuse of the product. For the purposes of IND safety reporting, ‚Äúreasonable possibility‚Äù means there are facts (evidence) or arguments to suggest a causal relationship between the drug and the adverse event..  Adverse events are to be considered unrelated if the relationship to the study drug, as described in the table in ¬ß 8.2.1,  is none or unlikely; whereas any AE reported in the study having a possible, probable or highly probable relationship to study drug will be considered as an ADR. The determination of expectedness should be made by [CONTACT_395848]. Serious Adverse Event A Serious Adverse Event (SAE) is defined in line with (CFR - Code of Federal Regulations Title 21 Sec. 312.32) as any adverse experience that, in the view of either the Investigator or sponsor, meets any of the following criteria:: x results in death, x is life-threatening (i.e. the patient was at immediate risk of death at the time of the event. It does not refer to an event which hypothetically might have caused death if it were more severe), x requires inpatient hospi[INVESTIGATOR_1081]. NOTE: In general, hospi[INVESTIGATOR_395818]/or treatment (usually involving an overnight stay) that would not have been appropriate in the physician's office or an outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to whether ‚Äúhospi[INVESTIGATOR_059]‚Äù occurred, the event should be considered serious. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 65 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 65 of 90  
x results in persistent or significant disability/incapacity. NOTE: The term disability means a substantial disruption of a person‚Äôs ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, or accidental trauma (e.g., sprained ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption x is a congenital anomaly/birth defect, x is an important medical event. NOTE: An important medical event is an event that may not result in death, be life threatening, or require hospi[INVESTIGATOR_6931] a SAE when, based upon appropriate medical judgment, it may jeopardize the patient‚Äôs wellbeing and may require medical or surgical intervention to prevent one of the outcomes listed in the definitions for SAEs. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in patient hospi[INVESTIGATOR_395819]-planned hospi[INVESTIGATOR_317836], not associated with any deterioration in condition are not considered to be SAEs (see Par. 8.3.2).   These events must be recorded in the AE page of the eCRF where a variable will be ticked to indicate that they are not SAEs.  Death shall always be reported as SAE and cause of death shall always be specified when known. Unexpected Adverse Event/Reaction An AE or ADR is considered unexpected if it is not listed in the Investigator Brochure or is not listed at the specificity or severity that has been observed and listed in the Investigator Brochure. Events that are mentioned in the Investigator Brochure (section Reference Safety Information)  as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation are considered unexpected (21 CFR312.32(a)). Suspected serious unexpected adverse reaction A suspected serious unexpected adverse reaction (S[LOCATION_003]R) is defined as an adverse reaction that is both unexpected (not consistent with the applicable product information) and also meets the definition of a Serious Adverse Reaction. As mentioned, the determination of expectedness should be made on the basis of the IB (section Reference Safety Information)  . Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 66 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 66 of 90  
Adverse Events (AEs) of special Interest (Sight-threatening Events) The following adverse events are considered to be of special interest and by [CONTACT_317895] (medically important criteria): ¬æ AEs that caused a decrease in visual acuity of >30 ETDRS letters or > +0.6 LogMAR (compared with the last assessment of visual acuity at the last visit) lasting >1 hour ¬æ AEs that caused a decrease in visual acuity to the level of Light Perception or worse lasting >1 hour ¬æ AEs that required surgical intervention (e.g., conventional surgery, vitreous tap or biopsy with intravitreal injection of anti-infectives, or laser or retinal cryopexy with gas) to prevent permanent loss of sight ¬æ AEs associated with severe intraocular inflammation (i.e., 4+ anterior chamber cell/flare or 4+ vitritis) ¬æ AEs that, in the opi[INVESTIGATOR_689], may require medical intervention to prevent permanent loss of sight. 8.2. ADVERSE EVENT (AE) MONITORING At visit 3 (end of treatment), visit 4 (FU), vist 5 (FU) and visit 6 (FU), after the patient has had the opportunity to spontaneously mention any problems, the Investigator or appropriate designee should inquire about AEs by [CONTACT_243932]:  x ‚ÄúHave you had any health problems since your last study visit?‚Äù x ‚ÄúHave there been any changes in the medicines you take since your last study visit?‚Äù  AEs should be reported for any clinically relevant change in concomitant condition(s) that is the result of an untoward (unfavorable and unintended) change in patient's medical conditions. Changes in any protocol-specific ocular or systemic parameter evaluated during the study are to be reviewed by [CONTACT_737]. In addition, the patient‚Äôs responses to any questionnaire utilized during the study are to be reviewed by [CONTACT_737]. Any untoward (unfavorable and unintended) change in a protocol-specific parameter or questionnaire response that is clinically relevant is to be reported as an AE. These clinically relevant changes will be reported regardless of causality. All AEs should be followed-up to determine outcome of the reaction.  In order to collect as complete as possible information in the clinical study database, all ADRs and SAEs ongoing at the time the subject‚Äôs study participation ends should be evaluated within 10 days after the final visit. After this period, all unresolved ADRs and SAEs will be reported as ‚Äúongoing‚Äù in the eCRF. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 67 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 67 of 90  
8.3. RECORDING AE data should be obtained through observation of the patient, from any information volunteered by [CONTACT_102], or through patient questioning.  Adverse Events: All AEs (non-serious and serious) that occur during the course of the study will be recorded in the eCRF. Any pre-existing medical conditions or signs/symptoms present in a patient prior to the start of the study (i.e., before informed consent is signed) should be specified in the dedicated eCRF sections. Subsequent to signing an informed consent form, all untoward medical occurrences that occur during the course of the study must be documented on eCRF. AEs will be collected till last Follow Up visit (week 16). When possible, signs and symptoms indicating a common underlying pathology should be documented as one comprehensive event. For each recorded event, the AE documentation must include the onset date, outcome, resolution date (if event is resolved), intensity (i.e., severity),any action with study treatment taken as a result of the event, and an assessment of the adverseevent relationship to the study treatment.   Serious Adverse Events: The Investigator must record all SAEs, including sight-threatening events, occurring at any time during the study regardless of presumed causal relationship, on the Serious Adverse Event form in the eCRF of the EDC system within 24 hours of learning of the event; information on the SAE must also be recorded on a specific Non-Carbon Repeat SAE form (included in the Investigator‚Äôs Site File).   Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 68 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497693] The Investigator will assess the possible relationship between the AE and the investigational medication, according to the criteria in Table below: Relationship of the Adverse Event to the IMP None (Intercurrent Event) An event that is not and cannot be related to the Investigational Product, e.g. patient is a passenger in a road traffic accident or surgical intervention performed during the study, but planned before patient enrolment into the study Unlikely (remote) Relationship is not likely e.g. a clinical event including laboratory test abnormality with temporal relationship to drug administration which makes a causal relationship improbable and in which other drugs, chemicals or underlying disease provide more plausible explanations Possible Relationship may exist, but could have been produced by [CONTACT_102]‚Äôs condition or treatment or other cause Probable Relationship is likely, the AE abates upon discontinuation of Investigational Product and cannot be due to the patient‚Äôs condition Highly Probable Strong relationship, the event abates upon discontinuation of Investigational Product and, if applicable, re-appears upon repeat exposure  An ADR is defined as an adverse experience which is reasonably likely to have been caused by [CONTACT_33641]. Events considered ‚ÄúPossible‚Äù, ‚ÄúProbable‚Äù and ‚ÄúHighly Probable‚Äù related to the IMP treatment and implying a reasonable possibility, if considered unexpected, will be reported to appropriate regulatory authorities. 8.3.2. Severity of AEs The Investigator will grade the severity of any AE using the definitions in the Table below. For each epi[INVESTIGATOR_1865], the highest severity grade attained should be reported. Severity of the Adverse Event Mild Grade 1 - Does not interfere with patient‚Äôs usual function (awareness of symptoms or signs, but easily tolerated [acceptable]). Moderate Grade 2 - Interferes to some extent with patient‚Äôs usual function (enough discomfort to interfere with usual activity [disturbing]). Severe Grade 3 - Interferes significantly with patient‚Äôs usual function (incapacity to work or to do usual activities [unacceptable])   Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 69 of 91
Study Protocol: NGF0118 
Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497694]  report  all SAEs  filling  in and  signing  a SAE  Report  form,  including  sight 
threatening  events,  regardless  of presumed  causal  relationship,  to Domp√©  Drug  Safety  and Syneos 
Health  Pharmacovigilance,  by e-mail  (preferred)  or fax  within  [ADDRESS_497695] details for SAE reporting are provided below: 
Syneos Safety reporting 
[EMAIL_1604] 
Domp √© Contac t information 
Domp√© Drug Safety   
Laura Boga, Senior Safety Manager  
Email: [EMAIL_1085] 
or Fax: [PHONE_1048] 
Domp√© Medical Expert   
[INVESTIGATOR_58256] ‚Äì Chief Medical Officer, 
Email:  [EMAIL_1086]  
or Fax:  [PHONE_1047] 
Pi[INVESTIGATOR_395796] ‚Äì Global Head Clinical Development 
Email:  [EMAIL_7577]  
or Fax:  [PHONE_1047] 
Domp√© Clinical Development  
Email:  [EMAIL_7579]/ [EMAIL_7578]/ [EMAIL_7580] 
or Fax: [PHONE_1047] 
Respecti ve IRB must also be infor med of a ll SAEs accordin g to loca l speci fic requirements. 
If assistanc e is neede d with the reporting of a SAE ,  Syne os Health/S ponsor may be contac ted at the 
addressed provided above  
Serious adve rse events will be manage d directl y by [CONTACT_395849]√© Drug Safet y departme nt, with Syneos 
Healt h support f or follow-up requests. 
The investigator  should  also report  information  on SAEs  that continue  after patient  has completed 
his/her  participation  in the study  (whether  study  completion  or withdrawal),  unless patient  has 
withdrawn his/her consent. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 70 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 70 of 90  
Follow-up reports (as many as required) should be completed and faxed/e-mailed following the same procedure above, marking the SAE form as ‚Äúfollow up Number XX‚Äù.   Whenever more than one SAE is observed, the Investigator should identify which is the primary adverse event, i.e. the most relevant one. If other events are listed in the same report, the Investigator, along with their relatedness to the Investigational Product, should identify which adverse events are serious and which are non-serious. In any case, the Investigator is requested to record his/her opi[INVESTIGATOR_395820](s) with the investigational medication. An assessment of expectedness and causality of each serious adverse event will be performed case by [CONTACT_58235]√©/Syneos Health. For SAE reported by [CONTACT_395850]√©, the Investigator will receive a notification. Depending on the nature and seriousness of the AE, further information, including copi[INVESTIGATOR_317837], as well as results of laboratory tests performed will need to be included in the patients chart. If the patient was hospi[INVESTIGATOR_057], a copy of the discharge summary should be available, if possible. In line with CT3 Detailed Guidance and ICH E2A provisions, although the Investigator does not usually need to actively monitor patients for AEs once the trial has ended, if the Investigator becomes aware of a SAE occurring to a patient after that patient has ended his/her participation in the study (whether study completion or withdrawal), the SAE should be reported by [CONTACT_395851]√©/Syneos Health Pharmacovigilance. Such ‚Äúpost-study cases‚Äù should be regarded for expedited reporting purposes as though they were study reports. Therefore, a causality assessment and determination of expectedness are needed for a decision on whether or not expedited reporting is required.  8.4.2. Conditions that should not be reported as serious adverse events The conditions listed below, that may require hospi[INVESTIGATOR_58170] a patient, are not considered to be SAE and shall not be reported as such, but only need to be recorded in the eCRF: x Hospi[INVESTIGATOR_317838].  x Hospi[INVESTIGATOR_58172], not associated with any deterioration in condition. x Hospi[INVESTIGATOR_243888], which was elective or pre-planned, for a pre-existing condition that is unrelated to the indication under study and did not worsen. x Hospi[INVESTIGATOR_58174].  x Treatment on an emergency, outpatient basis for an event not fulfilling any of the definitions of SAEs  given above and not resulting in hospi[INVESTIGATOR_063].  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 71 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 71 of 90  
In addition, the following situation shall not be considered SAE:  x Trial end points x Abnormal test results that do not induce clinical signs and/or symptoms and require intervention/therapy, i.e. are not clinically significant. 8.4.3. Reporting Procedure to IRB and to Regulatory Authorities In addition to reporting the SAE to Domp√©, the Investigator must also comply with the requirements related to the reporting of SAEs to the IRB which approved the study. The requirements of IRBs vary from one IRB to another; however, as a minimum requirement, the Investigators must promptly report all suspected unexpected serious adverse reaction (S[LOCATION_003]R) to their IRB. In line with provisions set forth in 21CFR312, Domp√© shall notify all participating Investigators in an IND safety report of any suspected adverse reaction that is both serious and unexpected  and of potential serious risks, from clinical trials or any other source, as soon as possible, but in no case later than:  x seven calendar days after becoming aware of the information if the event is fatal or life threatening; to be followed by [CONTACT_243934]. x fifteen calendar days after becoming aware of the information if the event is serious but neither fatal nor life threatening. The Investigators in turn shall notify their IRB.  If the results of an investigation show that an ADR not initially determined to be reportable is reclassified as reportable, the Sponsor shall report such reaction in a written safety report as soon as possible, but in no event later than 7/15 calendar days after the determination is made. Treatment will be unblinded by [CONTACT_58231]√© Drug Safety Pharmacovigilance prior to submission of a S[LOCATION_003]R to Regulatory Authorities and only cases referred to active treatment will be considered expeditable for regulatory reporting, in line with law requirements. Copi[INVESTIGATOR_395821]‚Äôs Files. Domp√© shall also notify FDA in an IND safety report of potential serious risks, from clinical trials or any other source, as soon as possible after Domp√© determines that the information qualifies for reporting, in particular shall notify of: x any suspected adverse reaction that is both serious and unexpected. Domp√© must report an adverse event as a suspected adverse reaction only if there is evidence to suggest a causal relationship between the drug and the adverse event.  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 72 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497696] a significant risk in humans exposed to the drug x increased rate of occurrence of serious suspected adverse reactions. 8.4.4. Periodical Reporting to Regulatory Authorities Domp√© shall be responsible to prepare and submit annual safety reports (Development Safety Update Report ‚Äì DSUR) to relevant Regulatory Authorities.  8.5. UNMASKING OF THE STUDY TREATMENT Masked information on the identity of the assigned investigational product will be provided for each patient. If the treatment code needs to be broken in the interest of patient safety, Domp√© must be informed in all cases in which the code was broken and of the circumstances involved. Additionally, Domp√© Drug Safety may be need to unmask the patient‚Äôs treatment if the a reported SAE meets criteria of a Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R) in order to fulfil expedited regulatory reporting requirements. Unmasked information shall not be disclosed to Investigators. The identity of the treatments will remain unknown to the patient, Investigator, site staff and Domp√©‚Äôs clinical research personnel and Syneos Health staff (apart from pharmacovigilance). 8.6. FOLLOW-UP OF PATIENTS WITH ADVERSE EVENTS (AES) The Investigator is responsible for adequate and safe medical care of patients during the trial and for ensuring that appropriate medical care and relevant follow-up procedures are maintained after the trial. All AEs should be followed-up to determine outcome of the reaction or until 10 days after the final visit. The Investigator should follow-up the event until resolution or stabilization of the condition. It is the Investigator's responsibility to assure that the patients experiencing AEs receive definite treatment for any AE, if required. If patient was hospi[INVESTIGATOR_58176] a SAE, a copy of the discharge summary is to be forwarded to Syneos Health/Domp√© as soon as it becomes available. In addition, a letter from the Investigator that summarizes the events related to the case as well as results of any relevant laboratory tests also may be requested. Further, depending upon the nature of the SAE, Domp√© may request copi[INVESTIGATOR_243885]‚Äôs medical records. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 73 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 73 of 90  
For pharmacovigilance purposes, all SAEs should be followed-up in order to elucidate as completely and practically as possible their nature and/or causality until resolution of all queries, clinical recovery is complete, laboratory results have returned to normal, stable condition is reached or the subject is lost to follow-up. Follow-up may therefore continue until after the subject has left the study up to  10 days after his/her discontinuation from the study for unrelated SAEs, and without timelines for related SAEs, unless the patient denies consent. 8.7. PREGNANCY IN THE CLINICAL TRIAL Women of childbearing potential are not excluded from the study as long as adequate birth control methods are being utilized. Women of childbearing potential are defined as all women physiologically capable of becoming pregnant. Adequate birth control methods are summarized in the protocol‚Äôs exclusion criteria. Prior to enrollment in the clinical trial, female patients of childbearing potential and their partners must be advised of the importance of avoiding pregnancy during the entire course of the study treatment and for the 30 days after the study treatment period ends and of the potential risks associated with an unintentional pregnancy. During the trial (during the study treatment period and during the follow up), female patients are to be instructed to contact [CONTACT_12696]; in the same way, male patients who become aware that the partner might be pregnant, are to be instructed to contact [CONTACT_201433].  The Investigator must report every pregnancy on a pregnancy report form as soon as possible (within 24 hours of learning of the pregnancy) to  Syneos Health/Domp√© Drug Safety contacts reported at Paragraph 8.4.1, even if no AE has occurred, and follow it to term.  The pregnancy form will be utilized to capture all pregnancy-related information until the birth of the child for both the patient and the partner.  If the pregnancy is associated with a SAE (eg, if the mother is hospi[INVESTIGATOR_16113]), in addition to the pregnancy report form, a separate SAE report form must be filed as described in ¬ß 8.4 with the appropriate serious criterion (eg, hospi[INVESTIGATOR_059]) indicated on the SAE report form. Miscarriage, stillbirth and any malformation/disease must be reported as a SAE. Any pregnancy leads to the immediate cessation of the study treatment.  8.8. ADVERSE EVENTS CAUSING TREATMENT DISCONTINUATION If a patient is withdrawn from the study as a consequence of an AE, this must be recorded and reasoned in the eCRF, and the patient must be followed up until the resolution of the AE or as instructed by [CONTACT_7195]. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 74 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 74 of 90  
8.9. OVERDOSE  Cases of overdose (accidental or intentional) which may or may not result in serious adverse reactions are to be reported to Sponsor Drug Safety/Syneos Health by [CONTACT_71345], following the same procedure for SAE, within 24 hours from the Investigator‚Äôs knowledge of its occurrence. This includes reports related to drug intake with suicidal intentions and consequent drug overdose. Since in the preclinical toxicology studies in animals and in the multiple ascending dose study performed in healthy volunteers none of the dose has caused an overdose as documented by [CONTACT_395852], for the purpose of this study we define that the administration of more than 3 times the total daily dose on any given treatment day will be reported as an overdose, even if not associated with adverse reactions. The Investigator shall provide in the SAE form information about symptoms, corrective treatment and outcome of overdose. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 75 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497697] deviation (SD), median, minimum, and maximum values for quantitative variables, and frequencies for qualitative variables. A statistical analysis plan (SAP) will be developed and finalized before database lock and de-masking. Final statistical analysis on the study variables will be presented in detail in the SAP.  9.1. SAMPLE SIZE In order to evaluate the minimal effective daily dose of rhNGF eye drops, a Williams design has been chosen [15; 16]. For this study three treatment groups has been considered: rhNGF eye drops solution 20 ¬µg/ml TID; rhNGF  eye drops solution 20 ¬µg/ml BID plus vehicle eye drop solution SID; vehicle eye drop solution TID. To this purpose, the sample size has been determined applying the formula eported in the publication Chow et al., 2008 at page 301 [17].   The sample size calculation for the primary variable is based on the following assumptions:  ¬É The probability level (Œ±) for one-sided test is set at 0.025 (see table 12.1.2 at page 298 in Chow et al., 2008) and the power level at approximately 90%.  ¬É DELTA, in change from baseline between treatments, of 5.[ADDRESS_497698] Deviation for DELTA of 10.78. Both DELTA parameters are derived from results of co-variance analysis obtained from study NGF0216 in the subset of hyposecretive patients (i.e. excluding ‚Äúevaporative-only‚Äù patients).  According to this calculation, 87 patients per treatment group (for a total of 261 patients) are adequate to observe the planned difference assumed for the minimum effective daily dose. Assuming a drop-out of ‚Åì15%, a total of [ADDRESS_497699] 60 subjects with documented diagnosis of Primary Sj√∂gren's Syndrome within the planned [ADDRESS_497700] on the initial study assumptions (Standard Deviation of 10.78 and DELTA of 5.3 mm) because the patients could have been enrolled based on the previous criteria on which sample size was based. Moreover, a similar prevalence of patients with Primary Sj√∂gren's Syndrome has already been reported in the NGF0216 medical history (‚Åì25% of patient the FAS population).  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 76 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497701] of all patients with all inclusion/exclusion criteria met. Otherwise the patient will be defined as screening failure.   Randomized Population  The Randomized Population will consist of all patients in the Screened Population who were assigned a randomization number.  9.3. COMPLIANCE WITH IMP ADMINISTRATION The assessment of patients‚Äô compliance to the IMP will be made by [CONTACT_395853] 1 Visit 1 baseline and the number of unused study medication vials returned at Week 4 Visit 3 End of treatment. The percentage Compliance will be evaluated according to the following formula: ùêéùêØùêûùê´ùêöùê•ùê• ùêúùê®ùê¶ùê©ùê•ùê¢ùêöùêßùêúùêû=ùüèùüéùüé‚àó(Number of vials dispensed ‚Äì Number of unused vials returned)ùüë‚àó(ùëµùíñùíéùíÉùíÜùíìùíî ùíêùíá ùíÖùíÇùíöùíî ùíêùíè ùíïùíìùíÜùíÇùíïùíéùíÜùíèùíï)  ùêÇùê®ùê¶ùê©ùê•ùê¢ùêöùêßùêúùêû ùêüùê®ùê´ ùê≠ùê°ùêû ùêûùê•ùê¢ùê†ùê¢ùêõùê•ùêû ùêûùê≤ùêû=ùüèùüéùüé‚àó(Number of  drops administered to the eligible eye)ùüë‚àó(ùëµùíñùíéùíÉùíÜùíìùíî ùíêùíá ùíÖùíÇùíöùíî ùíêùíè ùíïùíìùíÜùíÇùíïùíéùíÜùíèùíï)  Gross non compliance will be defined as compliance lower than 80% or greater than 120% and in case of gross non compliance the patient will be excluded from the Per Protocol. Since this definition does not warrant that the study eye treatment is compliant, if indicated the SAP will contain further definitions based upon the diary card information.  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 77 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497702] of all patients who signed the ICF. This analysis set will be used for demographic, baseline and background characteristics. Safety Population The Safety Population (SAF) will consist of all randomized patients who took at least one dose of IP. This analysis set will be used for the safety analysis. Patients will be analyzed according to the treatment received. Full Analysis Set Full Analysis Set (FAS) will consist of all randomized patients who took at least one dose of IP and who have at least one post-baseline efficacy measurement for the primary endpoint. This analysis set will be used for the primary efficacy analysis. Patients will be analyzed according to the randomized treatment. Per Protocol Set Per Protocol Set (PP) will consist of all patients in the FAS who fulfil the study protocol requirements in terms of investigational medicinal product intake and collection of primary efficacy data and with no major deviations that may affect study results. This analysis set will be used for supportive efficacy analysis.Patients will be analyzed according to the treatment received. Each patient will be coded by [CONTACT_395832], SAF, FAS and PP. 9.4.2. Reasons for exclusion from the Full Analysis Set Reasons for the exclusion from the Full Analysis Set are the following: ¬æ failure to take at least one dose of the IMP at the study eye ¬æ lack of any efficacy data post enrollment. 9.4.3. Reasons for exclusion from the Per Protocol set Reasons for the exclusion from the Per Protocol set will be determined in the Blind Data Review Meeting and can be the following: Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 78 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 78 of 90  
¬æ lack of compliance with IMP administration  ¬æ missing primary efficacy data ¬æ major deviation from inclusion/exclusion criteria (eligibility violations) ¬æ intake of prohibited medications. 9.4.4. Demographic and baseline characteristics Demographic and baseline characteristics will be descriptively summarized per treatment group according to their nature.  9.5. Analysis of ophthalmological evaluations  Primary endpoint will be analyzed using analysis of variance including only the treatment as main factor followed by [CONTACT_094]-planned comparisons from Vehicle and rhNGF dosages according to Williams procedure. In addition, primary endpoint will be summarized using descriptive statistics for continuous variables by [CONTACT_10659]. The change from baseline value will also be summarized for all post-baseline visits. An explorative sensitivity analysis of the primary endpoint will be conducted including in the analysis of variance the absence/presence of diagnosis of Primary Sj√∂gren's Syndrome and its interaction with treatments as covariates. If the interaction term is statistically significant (at the 0.10 level given its explorative nature), the treatment effects within patients with and without Primary Sj√∂gren's Syndrome will be provided.  Secondary endpoints will be presented by [CONTACT_395833].  Changes from baseline in global SANDE score, Schirmer test II, NEI scales, TFBUT,  IDEEL, PGIC and EQ-5D-3L scores [ADDRESS_497703] I (primary endpoint) in order to test treatment effect. Difference between treatment groups (Each active dose vs Placebo), in the percentage of patients who experienced a worsening in SANDE scores and/or NEI score will be tested using a chi-square test.  Explorative endpoints will be summarized by [CONTACT_395833]. Any statistical testing will be descriptive in nature.  Additional details on the analyses will be provided in the statistical analysis plan.  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 79 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 79 of 90  
9.5.1. Analysis of safety variables x AEs Adverse events (AEs) will be coded by [CONTACT_1196] (SOC) and Preferred Term (PT), using the Medical Dictionary for Regulatory Activities (MedDRA). Treatment-emergent AEs are all events occurring or worsening after the first dose of the IMP. Treatment-emergent AEs will be summarized by [CONTACT_1570]. The number and percentage of patients with any AE and the number of TEAEs will be tabulated by [CONTACT_3592], seriousness, relationship to treatment and severity. Individual AEs will be listed in patient data listings.   9.5.2.  Analysis of Quality of Life variables  Data record in the questionnaires of quality of life will be presented with appropriate descriptive statistics and processed with appropriate inferential test.  9.5.3. Subgroup analysis Sub-group analyses of primary, secondary, explorative endpoints and safety endpoints will be performed on patients with the Sj√∂gren's syndrome  for explorative purpose. Statistical details will be reported in the SAP.  9.5.4. Changes to the statistical plan Any deviations from the original statistical plan will be escribed in the Clinical Study Report. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 80 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497704] (IRB) before the start of the study will be the responsibility of the Principal Investigator (PI). A copy of the approval letter will be supplied to the sponsor, along with a roster of IRB members or the US Department of Health and Human Services (DHHS) general assurance number. During the course of the study, the PI [INVESTIGATOR_317843], at intervals not exceeding 1 year (or as appropriate), and will notify the IRB of serious adverse events (SAEs) or other significant safety findings. The study protocol, informed consent form (ICF), information sheet advertisements, and amendments (if any) will be approved by [CONTACT_395854] (CFR), Title 21, Part 56.  10.2. ETHICAL CONDUCT OF THE STUDY  The study will be conducted in full compliance with FDA and ICH guidelines for good clinical practice (GCP) and in accordance with the ethical principles that have their origins in the Declaration of Helsinki and 21 CFR ¬ß 312.120.  10.3. DATA MONITORING COMMITTEE A Data Monitoring Committee is not required for this trial considering the following point: x The drug under investigation is well characterized and known for not harming patients x Tis clinical trial does not foresee an interim analysis x The study design is not complex and already performed in other clinical trial in DED x The study does not have a long duration. 10.4. PATIENT INFORMATION AND CONSENT  Patients, after being given an explanation of the study, will give voluntary and written informed consent before participating in any study-related procedures. A copy of the Experimental Subject‚Äôs Bill of Rights (Footnote 1) will provided to a subject prior to performing the consent process. Each patient will read or be read (if he or she cannot read or write), assent understanding of, and sign or thumbprint an instrument of informed consent and after having had an opportunity to discuss them   [ADDRESS_497705] ([LOCATION_004] Health and Safety Code [ZIP_CODE] ‚Äì [ZIP_CODE].5) requires that a potential experimental subject (or subject‚Äôs conservator, guardian, or other representative) be provided with a list of the rights of a subject in a medical experiment. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 81 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 81 of 90  
with the PI [INVESTIGATOR_317844]; each patient will be made aware that he or she may withdraw from the study at any time.   The informed consent statement contains all the elements of informed consent and contains all the core elements and mandatory statements as defined in the CFR. Signed copi[INVESTIGATOR_395822], and both documents will be placed in the Investigator‚Äôs site files. A unique patient identification (PID) number will be assigned according to ¬ß 4.[ADDRESS_497706] of the study will be regarded as confidential. An agreement for disclosure will be obtained in writing by [CONTACT_243937]. Patient‚Äôs data collected during the study will be handled in accordance with applicable data protection laws and regulations.  On the CRFs patients will be identified ONLY by [CONTACT_16790]. If patient names are included on copi[INVESTIGATOR_317846]√© farmaceutici s.p.a. or Syenos Health, the names will be obliterated or masked and the assigned patient number added to the document. The Investigator should keep a separate log (Patient Master List) of patient‚Äôs codes, names and addresses. 10.6. COMPENSATION FOR MEDICINE-INDUCED INJURY AND INDEMNIFICATION Before the trial formally starts, Domp√© will take out a study-specific insurance contract according to national laws for patients/Investigators/Institutions participating in the clinical trial.   In case of questions about medical care, cost for medical care or insurance, patients can talk to their Investigator. Contact [CONTACT_243938].   Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 82 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497707] access. In addition to periodic monitoring occurring within the system by [CONTACT_395855], programmatic edit checks will be used to review the data for completeness, logic, and adherence to study protocol. As a result of this monitoring and these checks, queries may be electronically issued to the study centers and electronically closed by [CONTACT_243939]. The identifying information (assigned username, date, and time) for both the originator of the query (if created during the monitoring process) and the originator of the data change (if applicable), as well as the PI‚Äôs approval of all changes performed on his or her patients‚Äô data, will be collected.  All data collected in the context of this study will be stored and evaluated per regulatory requirements and applicable guidances for electronic records. Also, data will be stored and evaluated in such a way as to guarantee patient confidentiality in accordance with the legal stipulations applying to confidentiality of data. Study records (e.g., copi[INVESTIGATOR_1495], regulatory documents) will be retained at the study center, along with adequate source documentation, according to FDA and ICH requirements. All study records must be available for audit  by [CONTACT_58231]√© farmaceutici s.p.a.; its authorized representatives; and Regulatory Inspection by [CONTACT_243940].  The investigator/institution should maintain adequate and accurate source documents and trial records that include all pertinent observations on each of the site‚Äôs trial subjects. Source data should be attributable, legible, contemporaneous, original, accurate, and complete. Changes to source data should be traceable, should not obscure the original entry, and should be explained if necessary via an audit trail. 11.3. DOCUMENTATION REQUIRED PRIOR TO INITIATION OF AND DURING THE STUDY The following documents will be required from the Investigator prior to the initiation visit: - Current, signed and dated Curriculum Vitae of Principal Investigator [INVESTIGATOR_219793]-Investigators/co-workers. Updates should be provided at least every two years. - A signed page of the final protocol and any amendments. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 83 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 83 of 90  
- A signed copy of the study Financial Agreement/Clinical Study Agreement with Syneos Health, including all study specific costs. - List and any updates of delegated responsibility (Study Team Signature [CONTACT_46979] / Delegation of Responsibilities form).  - A financial disclosure agreement completed and signed by [CONTACT_978] [INVESTIGATOR_244293]-Investigators listed on Form FDA 1572. If applicable, the PI [INVESTIGATOR_317850] 1 year after the completion of the study. 11.4. ESSENTIAL DOCUMENT RETENTION The Investigator will retain copi[INVESTIGATOR_285421] (as defined by [CONTACT_12212]-GCP E6 R2) until at least [ADDRESS_497708]: the signed protocol, copi[INVESTIGATOR_395823], signed Patient Informed Consent Forms from all patients who consented, hospi[INVESTIGATOR_285423], and all other documentation included in the Investigator Site File and Pharmacy/Dispensing File. The Investigator will inform Domp√© farmaceutici s.p.a. of the storage location of these essential documents and must contact [CONTACT_58231]√© farmaceutici s.p.a. before disposing of any. If the Investigator wishes to assign the files to someone else or to remove them to another location, he/she should consult with Domp√© farmaceutici s.p.a. about this change. Domp√© farmaceutici s.p.a. will inform the Investigator in writing when these documents no longer need to be retained. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 84 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 84 of 90  
12. STUDY MANAGEMENT  The study will be performed in accordance with the protocol, the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013) and ICH Harmonised Tripartite Guideline for Good Clinical Practice (ICH-GCP E6-R2) and any local regulations. 12.1. MONITORING Before any patient enters the study, a representative of Syneos Health, will meet with the PI [INVESTIGATOR_395824] (EDC) system. After the first patient is enrolled, the Syneos Health representative, a monitor, will periodically monitor the progress of the study by [CONTACT_143505]-site visits. This CRA will also be able to review query statuses remotely, possibly warranting more frequent communication with the PI [INVESTIGATOR_317853]. The PI [INVESTIGATOR_317854], source documents, signed consent forms, and all other study-related documents. The PI [INVESTIGATOR_395825], resolving data queries generated by [CONTACT_317917], providing missing or corrected data, approving all changes performed on his or her data, and endorsing the patient data within the EDC system. This approval method will include applying an electronic signature, a uniquely assigned username [CONTACT_357926] a traditional handwritten signature.  12.2. ACCESS TO RECORDS The Investigator will allow designated Domp√© farmaceutici s.p.a. representatives, including staff from Syneos Health, and regulatory/ethics bodies to have direct access to the source documents to verify the data reported in the eCRFs. Source documents are the originals of any documents used by [CONTACT_192162][INVESTIGATOR_307]/institution that allow verification of the existence of the patient and substantiate the integrity of the data collected during the trial. 12.3. AUDIT AND INSPECTION The study site may be audited by [CONTACT_395856]√© farmaceutici s.p.a. or inspected by a regulatory agency on one or more occasions. The Investigator may be informed in advance of such a visit.  12.4. PROTOCOL AMENDMENTS Any amendment to this protocol will be provided to the PI [INVESTIGATOR_243893]√© farmaceutici s.p.a. No protocol amendment may be implemented (with the exceptions noted below) before it has been Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 85 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/[ADDRESS_497709] to mutual agreement between the PI [INVESTIGATOR_243894]√© farmaceutici s.p.a. The Sponsor agrees that the study results (including negative and inconclusive as well as positive results) can be made publicly available by [CONTACT_317919]; presenting results at scientific congresses; and posting information and results on internet-based public registers and databases. In any case, study results will be communicated in full to the FDA by [CONTACT_58251] a complete Clinical Study Report. As the Sponsor agrees that the study results can be published by [CONTACT_737](s), the Investigator agrees to submit any manuscript (abstract, publication, paper etc.) to the Sponsor before any public disclosure. This will be done in order to ensure that clinical trial results are reported in an objective, accurate and balanced manner. The Sponsor reviews proposed manuscripts prior to submission within a reasonable period of time (30-90 business days in relation with the complexity of the work). The Investigator(s) will also be provided by [CONTACT_395857], tables, figures etc undertaken for the purposes of the article, in order to take responsibility for the content of the publication(s). On an exceptional basis, the Sponsor may temporarily delay registration of certain data elements (e.g. compound, name, outcome, measures etc.) to seek necessary intellectual property protection. This is because early disclosure of such a data could, in some circumstances, prevent or negatively impact patentability.  Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 86 of 91
    Study Protocol: NGF0118  
 Version No. 2.0 ‚Äì Final 08/AUG/2019  CONFIDENTIAL   Page 86 of 90  
13. REFERENCES 1 Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care 2008; 14([ADDRESS_497710]):S102-6. Review.  2 TFOS DEWS II REPORT. Ocul Surf 2017; 15(3):269-283...  3 Lambiase A, Sacchetti M and Bonini S, Nerve growth factor therapy for corneal disease, Curr Opin Ophthalmol 2012, 23:296‚Äì302.  4 Nguyen D, Beuerman HRW, Thompson HW, et al. Growth factor and neurotrophic factor mRNA in human lacrimal gland. Cornea 1997; 16(2):192‚Äì9.  [ADDRESS_497711] Ophthalmol Vis Sci 2003; 44(8):3352‚Äì7.  [ADDRESS_497712] Ophthalmol Vis Sci 2000, 41(8): 2138‚Äì47.  7 Coassin M, Lambiase A, Costa N, et al. Efficacy of topi[INVESTIGATOR_317856]. Graefe‚Äôs Arch Clin Exp Ophthalmol 2005;243(2):151-5.   8 Lee HK, Ryu IH, Seo KY, et al. Topi[INVESTIGATOR_2855] 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmology 2006; 113(2):198-205.   9 Bonini S, Lambiase A, Rama P, et al. Topi[INVESTIGATOR_395826]. Ophthalmology 2000; 107:1347-51.  [ADDRESS_497713] Ophthalmol Vis Sci 2007; 48(4):1543-51.  11 Lambiase A, Rama P, Bonini S, et al.Topi[INVESTIGATOR_395827]. New Engl J Med 1998; 338(17):1174-80.  [ADDRESS_497714], Aloe L, et al. Anti-inflammatory and healing properties of nerve growth factor in immune corneal ulcers with stromal melting. Arch Ophthalmol. 2000; 118(10) p1446-1449.  13 Bonini S, Lambiase A, Rama P, et al. Topi[INVESTIGATOR_395826]. Ophthalmology 2000; 107:1347-51.  14 Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sj√∂gren‚Äôs syndrome: a revised version of the European criteria proposed by [CONTACT_317921]-European Consensus Group. Ann Rheum Dis 2002; 61:554‚Äì558.  [ADDRESS_497715] for differences between treatment means when several dose levels are compared with a zero dose control.  1971. Biometrics 27, 103-117 16 Williams DA. The comparison of several dose levels with a zero dose control.  1972. Biometrics 28, 519-531.  17 Shein-Chung Chow, Jun Shao, Hansheng Wang;  Samples Size Calculations in Clinical Research - Marcel Dekker, Inc. 2003I, SBN: 0-8247-0970-5, p. 186-189. Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 87 of 91
Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 88 of 91
 
   S t u d y  Protocol: NGF0118  
 
 
Version No. 2.0 ‚Äì Final 08/AUG/2019  C O N F I D E N T I A L  
  
Page 88 of 90 
 
14.2 APPENDIX 2-INVESTIGA TOR‚ÄôS SIGNATURE [CONTACT_317924]‚Äôs Statement  
 
I have read study protocol NGF0118 from the title  ‚ÄúA [ADDRESS_497716] or (rhNGF) eye drops solution versus vehicle, 
in patients with moderate to severe dry eye (DE) ‚Äù and agree to conduct the study as outlined in the 
protocol, and in accordance with  t h e  D e c l a r a t i o n  o f  H e l s i n k i , ICH-GCP E6 (R2) and any local 
regulations, being responsible for personally supervi se the study conduct and ensure study staff 
complies with protocol requirement. 
 
 
Name [CONTACT_789] (block letters):____________________________________________ 
 
 
 
Signature:  _______________________________  Date:  _________________________  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 89 of 91
 
   S t u d y  Protocol: NGF0118  
 
 
Version No. 2.0 ‚Äì Final 08/AUG/2019  C O N F I D E N T I A L  
  
Page 89 of 90 
 
14.3 APPENDIX 3AMERICAN-EUROPEAN CONSENSUS CRITERIA FOR SJ√ñGREN ‚ÄôS 
SYNDROME 
 
Reference:  Vitali C, et al. Cla ssification criteria for Sjogre n‚Äôs syndrome: a revised version of the 
European criteria proposed by [CONTACT_317921] -European Consensus Group. Ann Rheum Dis 2002; 
61:554-558. 
In order to make a d iagnosis of Sj√∂gren‚Äôs syndrome, the following criteria must be met: 
I. Ocular Symptoms (at least one) 
x Symptoms of dry eyes for at least 3 months 
x A foreign body sensation in the eyes 
x Use of artificial tears 3 or more times per day 
II. Oral Symptoms (at least one) 
x Symptoms of dry mouth for at least 3 months 
x Recurrent or persistently swollen salivary glands 
x Need for liquids to swallow dry foods 
III. Ocular Signs (at least one) 
x Abnormal Schirmer‚Äôs test, (without anesthesia; ‚â§5 mm/5 minutes)  
x Positive vital dye staining of the eye surface 
IV. Histopathology 
x Lip biopsy showing focal lymphocytic sialoadenitis (focus score  ‚â•1 per 4 mm2)  
V. Oral Signs (at least one) 
x Unstimulated whole salivary flow (‚â§1.5 mL in 15 minutes)  
x Abnormal parotid sialography 
x Abnormal salivary scintigraphy 
VI. Autoantibodies (at least one) 
x Anti-SSA (Ro) or Anti-SSB (La), or both 
For a primary Sj√∂gren‚Äôs syndrome diagnosis:  
x Any [ADDRESS_497717] include either item IV (Histopathology) or VI (Autoantibodies) 
x Any 3 of the 4 objective criteria (III, IV, V, VI)  
 Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 90 of 91
 
   S t u d y  Protocol: NGF0118  
 
 
Version No. 2.0 ‚Äì Final 08/AUG/2019  C O N F I D E N T I A L  
  
Page 90 of 90 
 
For a secondary Sj√∂gren‚Äôs syndrome diagnosis:  
x In patients with another well-defined maj or connective tissue disease, the presence of one 
symptom (I or II) plus 2 of the 3 objective criteria (III, IV and V) is indicative of secondary 
SS. 
Exclusion Criteria 
x Past head and neck radiation treatment 
x Hepatitis C infection 
x Acquired immunodeficiency syndrome (AIDS) 
x Pre-existing lymphoma 
x Sarcoidosis 
x Graft versus host disease 
x Current use of anticholinergic drugs 
 
 Domp√© farmaceutici s.p.a.   Recombinant Human Nerve Growth Factor (rhNGF) NGF0118 Final ___________________________________________________________________________________________________________________________________________________________
This document is confidential.Page 91 of 91